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ABSTRACT

SYNTHESIS AND EVALUATION OF NOVEL IODINE-124 LABELED
NUCLEOSIDE ANALOGS AS PET IMAGING AGENTS TO PREDICT
RESPONSE TO GEMCITABINE THERAPY
by
Kishore Kumar Gangangari

Advisors: Shengping Zheng and NagaVaraKishore Pillarsetty

Gemcitabine (gem) is a nucleoside analog that is used to treat pancreatic cancers (PaCa),
which have dismal prognosis and low survival rate. Though gem is used as first line of treatment
for PaCa, the response rate is quite low (~30%). Currently, there is no a priori way to determine a
responder from a non-responder to gem therapy either invasively or non-invasively. Any
biomarker that can act as a prognostic indicator of gem response will greatly aid in selecting
responsive patients to gem therapy and provide alternative options such as Folfirinox or other
treatments to resistant patient population. Amongst various known biomarkers, deoxycytidine
kinase (dCK) is considered to be an important rate limiting enzyme that is necessary to convert
gem into its cytotoxic derivative and therefore, levels of dCK in tumors could aid in predicting the
drug’s efficacy to treat cancers and patient response to therapy.
Investigation into synthesis of novel radioactive-iodine (radioiodine) labeled gem analogs,
2′-fluoro-2′-deoxy-1-β-D-ribofuranosyl-5-iodocytosine (FIRC), 2′,2′-difluoro-2′,2′-dideoxy-1-β–
D-furanosyl-5-iodocytosine

(5-Iodogemcitabine,

IGem)

and

2′-Fluoro-2′-deoxy-1-β-Div

arabinofuranosyl-5-iodocytosine (FIAC) and their evaluation as potential to predict dCK levels in
pancreatic tumor cell lines will be described. The most promising iodine labeled gem analog, FIAC
will be described in detail and potential of [124I]FIAC as an imaging agent to image various
pancreatic tumors over extended periods of time by PET (positron emission tomography) to
provide a better tumor to background ratio will be evaluated. Further, it will be compared to 1-(2′deoxy-2′-[18F]fluoro--D-(arabinofuranosyl)cytosine) ([18F]FAC), which has been previously
investigated as a surrogate marker for dCK.
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CHAPTER 1: INTRODUCTION
1.1

Gemcitabine

Gemcitabine (2′,2′-difluoro-2′-deoxycytidine, dFdC or gem, 1, Figure 1.1) is a
chemotherapeutic agent used in the treatment of various kinds of solid tumors. It is used either as
a single agent or in conjunction with radiation, and is the most commonly used therapeutic
paradigm for the management of pancreatic cancer (PaCa).1, 2 Gem inhibits DNA replication and
induces cell-apoptosis to elicit its anti-tumoral effect.
Chemically, it bears a close structural resemblance to naturally occurring pyrimidine
nucleoside, deoxycytidine (dC, 2). Two hydrogens on 2′ position of dC are substituted geminally
with two fluorine atoms. While fluorine and hydrogen atoms are similar with respect to Van der
Waal’s radii (1.35 Å and 1.20 Å respectively), they are chemically polar opposites because of
major difference in the electronegativity of fluorine and hydrogen. Such close resemblance in
structure, yet different chemical properties is a major reason for the cytotoxic properties of gem.

Figure 1.1. Structural details of a) gemcitabine (2′,2′-difluoro-2′,2′-dideoxycytidine, gem, 1) and
b) deoxycytidine (dC, 2)

1

Patent publication describing the synthesis of gem and its evaluation as an antiviral is the
earliest reference to gem (1983).3 Synthesis of gem was published by Hertel et. al. of Lilly
Research Laboratories, Indiana in 1988 as a part of Lilly’s program to design and synthesize
nucleosides of potential value as anticancer and/or antiviral agents (Fig 3). 4 This novel synthesis
(Scheme 1.1.) of 2′,2′-disubstituted sugar, 2′-deoxy-2′,2′-difluoro-D-ribose (10), utilized the
reaction scheme starting from (R)-2,3-O-isopropylideneglyceraldehyde (5) and can be compared
to a previously reported synthesis by Hanzawa et. al. using a Reformatsky reaction of
bromodifluoromethylacetylene.5 While patented as an antiviral initially, gem was later evaluated
as an anti-cancer agent and compared to 1-β-D-arabinofuranosylcytosine (ara-C, 3 Fig 1.2.), the
most effective anti-cancer drug of that era to treat adult acute leukemia which is still highly
effective and in use today.6 Gem was significantly more cytotoxic than ara-C in Chinese hamster
ovary cells and the major metabolite was 5′-triphosphate form (85-90%). No cytotoxic effects were
observed in cells deficient in an enzyme deoxycytidine kinase which catalyzes the rate-limiting
step responsible for cytotoxic effects of gem and ara-C. The cytotoxic effects were later confirmed
in vivo by evaluating gem in murine solid tumors7.
Gem was evaluated in vivo in murine models followed by clinical trials in humans shortly
afterwards.1, 8-10 Gem was approved by the FDA in 1996 for the therapy of locally advanced (nonresectable grade II and III) or metastatic (stage IV) pancreatic adenocarcinoma. Later approvals
followed for non-small cell lung cancer (inoperable locally advance IIIA/IIIB and metastatic grade
IV), breast cancer (with paclitaxel) and ovarian cancer (with carboplatin). Even 30 years after
discovery, there are around 650 active clinical trials involving various aspects of gemcitabine
highlighting

its

tremendous

sustained

impact

and

its

utility

in

chemotherapy

(https://www.clinicaltrials.gov accessed on June 5th, 2018).
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Scheme 1.1. Original synthetic route gemcitabine

Figure 1.2. Structure of 1-β-D-arabinofuranosylcytosine (ara-C, 3)
3

1.2

Challenges to gemcitabine therapy

1.2.1

Dismal prognosis in pancreatic cancer patients

Despite being the best choice among existing chemotherapeutics, gem faces its own
challenges, especially in the treatment of pancreatic cancers. Pancreatic cancer is one of the most
lethal kinds of cancers and is virtually symptom free in early stages and detected only in late
stages.11 Surgical resection is the only curative treatment in early disease stage. Confoundingly,
the symptoms present only in advanced disease at which point the cancer cells metastasize rapidly
to other organs making resection almost impossible.12
When gem is used as a single agent to manage pancreatic cancer (PaCa), only 23.8% of the
patients experience clinical benefit with a median survival duration of 5.65 months and 18%
survival rate over 12 months.1,
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Despite various attempts to improve patient outcomes, the

prognosis has not improved substantially over the last 20 years and pancreatic cancer still remains
the fourth leading cause of cancer related deaths.11 Only a subset of patients who are treated with
gem show any meaningful benefit. For example, in a recent study only 23% of the patients treated
with gem postoperatively, showed a disease-free survival (DFS) of 5 years.13
Poor prognosis can be explained epidemiologically with factors such as heterogeneity in
patient population and cancer types, stage of the cancer at the beginning of treatment cycle, onset
of the treatment, ethnic background of patients. Despite such range in the response to gem
treatment, no correlation to any factor has been found yet. Even at the molecular level, there has
been no unique factor or a biomarker that has shown to be consistently associated the patients’
ability to respond to therapy or lack thereof. Not only the response, but the toxicity levels and
development of resistance to gem could not be clearly associated to a unique biomarker. Reasons
for such dismal prognosis and variability in patient response needs better understanding of
4

underlying molecular mechanism of action of gem. As for any other chemotherapeutic, knowledge
of gem’s cellular pharmacology and other molecular targets may also be pivotal to a more selective
and appropriate use of this drug in treating pancreatic cancers by understanding the biomarkers
responsible for response to therapy.14
1.2.2

Mechanism of action

Initial understanding of gem’s mechanism of action was based on known pharmacology of
existing nucleoside anti-neoplastics. Many comprehensive reviews have been compiled describing
gem’s mechanism of action.15, 16 The following description is a condensed synopsis of the current
state of the literature describing the pathways involved in the gem’s metabolism as elucidated in
Figure 1.3.
Gem is commonly referred to as a cytotoxic “prodrug” instead of a drug, alluding to the
fact that gem does not confer any cytotoxicity itself and must be activated. Prodrugs undergo
metabolism in the human body to form their active metabolites (or drugs) to elicit their effect.
Gem is administered as a continuous intravenous infusion as a single agent or in combination with
other antimetabolites/cytotoxic agents. Once gem reaches the cells post-administration, the
metabolic fate of gemcitabine can be divided into three main steps which affect the drug efficacy
- 1) transportation across cell membrane 2) cellular phosphorylation and 3) incorporation into
DNA.
Gem is a hydrophilic molecule and relies on membrane transporters for its uptake into cells.
There are two types of transporters – sodium-independent human equilibrative nucleoside
transporters (hENT1, subtypes - SLC29A1 and SLC29A2) and sodium-dependent human
concentrative nucleoside transporters (hCNTs, subtypes SLC28A1, SLC28A2 and SLC28A3).
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SLC29A1 facilitates the diffusion of most of purines and pyrimidines and is reportedly the most
important transporter responsible for gem uptake.17
Following transport into the cell across the cell-membrane, gem undergoes a series of
phosphorylations before it can incorporate into cellular DNA as gem-triphosphate (gem-TP).
Among the series of phosphorylations, the first phosphorylation to form gem-monophosphate
(gem-MP) is catalyzed by deoxycytidine kinase (dCK). Gem has very high affinity for dCK (K m
= 3.6 – 4.6 µM) and phosphorylation by dCK is the rate-limiting step in the activation of gem.6
Gem-MP undergoes further phosphorylations to generate diphosphorylated-gem (gem-DP) and
finally the gem-TP, the active drug form of gem. Gem-TP is structurally similar to deoxycytidinetriphosphate (dCTP), the natural substrate in DNA backbone. Gem-TP is incorporated into DNA
undergoing replication, masquerading as CTP. The base-excision repair mechanism that detects
the mismatch in DNA base pairs is masked by the addition of an extra nucleotide after gem addition
and the process of DNA elongation stalls. Such irreparable termination of DNA elongation leads
to DNA damage which eventually leads to apoptosis. Significant chemotherapeutic effect of gem
is attributed to gem-triphosphate that integrates into elongating DNA. Gem-TP is also an inhibitor
of an enzyme DNA polymerase that is essential for DNA replication.

6

Figure 1.3. Mechanism of action of gemcitabine
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Along with gem-TP, other phosphorylated forms of gem are also resposible for the overall
cytotoxicity of gem. Gem-DP inhibits ribonucleotide reductase (RR) and actively decreases the
deoxyribonucleotide pools in the cell. RR catalyzes the synthesis of deoxyribonucleotides from
ribonucleotides in nucleoside de novo synthesis pathways. Decreasing the deoxyribonucleotide
concentration favors gemcitabine uptake. Low concentrations of native deoxycytidines promote
dCK activity and inhibit deoxycytidylate deaminase activity. This feedback-mechanism of
synergistically increasing apoptosis is widely referred to as “self-potentiation.”18 Such multi-prong
approach elicited by all major metabolites of gem, leads to the excellent anti-tumor activity.19
While various enzymes are involved in the activation of gem to form active metabolites,
majority of gem (~90%) is inactivated by deamination by cytidine deaminase (CDA) to form
difluorodeoxyuridine (dFdU).20 Additional inactivation steps in pathway occur on gem-MP, which
could undergo deamination by deoxycytidylate deaminase or dephosphorylation by 5′nucleotidases. These inactivation steps ultimately decrease the amount of the active metabolites,
gem-DP and gem-TP, responsible for gem’s cytotoxicity.
This robust and detailed understanding of gem mechanism of action gives insights into
potential biomarkers for therapeutic response, which could be further utilized to differentiate
responders and non-responders. This intricate mechanism also highlights the complex interplay of
various cell processes that are needed for gem’s activity and obscures the most relevant targets
responsible for the differential response to patients to gem. It can be inferred that gem is more
effective in those cancer types where there is an up-regulation of nucleoside transporters,
deoxycytidine kinase (dCK), other kinases and down-regulation of cytidine deaminase and
ribonucleotide reductase.

8

1.2.3

Differentiating responders and non-responders

While the role of key transporters and enzymes has been implicated in sensitizing or
conferring resistance to gem, no clear correlation has been established using genetic analysis of
tumor cells and tumor biopsies.21-23 Currently, there is no a priori way to determine invasively or
non-invasively which pancreatic cancer patients stand to benefit from gem therapy. Any biomarker
that can act as a prognostic indicator of gem response will greatly improve oncologists’ ability to
manage and treat cancer. Such categorization of patient population into responders (gem
responders) and non-responders (gem non-responders) can help both populations of PaCa patients.
Non-responders could be treated with early aggressive combination therapies such as
FOLFIRINOX.24 FOLFIRINOX is a highly aggressive combination drug therapy consisting of
potent but toxic components including oxaliplatin, leucovorin, irinotecan and 5-fluorouracil on
the same day mostly as a slow infusion that in total lasts around 5 h. This is followed by a
continuous intravenous infusion of 2400 mg/m2 over a 46-hour period, every 2 weeks. While the
grade 3 and 4 adverse effects (AE) were significantly higher (68% patients exhibiting hematologic
AE with FOLFIRINOX treatment compared to 33.6% with gem alone), the efficacy of
FOLFIRINOX is significantly better as well (0.6% patients showing complete response compared
to 0% with gem alone and 31.0% showing partial response compared to 9.4% with gem alone).
The median overall survival was 11.1 months (95% CI, 9.0 to 13.1) in the FOLFIRINOX group
as compared with 6.8 months (95% CI, 5.5 to 7.6) in the gemcitabine group. Also, such patients
could make use of promising new investigational drugs in clinical trials such as immunotherapy.25
There are at least 75 active trails studying the use of immunotherapeutic agents in pancreatic
cancers worldwide, of which 54 are being conducted in USA (clinicaltrials.gov accessed
12/27/2018).
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Aggressive therapies that marginally benefit patients are generally avoided as first line of
treatment because of their adverse side effects.26 Gemcitabine therapy typically lasts for 10-11
weeks.1 If a biomarker can identify a gem non-responder, more aggressive or novel therapies can
be administered directly instead of first line of therapy with gem that typically lasts for 10-11
weeks and has significant side effects. Adverse-effects of gem are mainly attributed to bone
marrow suppression that leads to pancytopenia (deficiency of red blood cells, white blood cells,
and platelets).
1.3

Strategies to predict response to gemcitabine therapy in pancreatic cancer patients
1.3.1

Conventional methods to correlate biomarkers to gem response

Several efforts have been made to identify factors that can predict the probability and
magnitude of patient’s response to gem therapy, ranging from computational methods to
correlating various biomarkers in patient tumor samples.27, 28 While in silico and in vitro methods
only predict the probability, the most accurate representation of various biomarkers can only be
obtained from analyzing the patient samples. Currently, a number of methods are available to
assess the levels of various markers in the cancer cells. Some examples of these methods are staining, gene sequencing (DNA and RNA), proteomics, flow-cytometry and western blots.
Despite the availability of advanced techniques to determine the levels of various biomarkers in
the tissue, they all inherently depend on the availability of patient tumor samples. These samples
are normally obtained from patients by performing needle biopsies that are invasive in nature.
Moreover, the analytical methods to measure the levels of biomarkers are time-consuming and
slow. More importantly, pancreatic cancers are heterogeneous at functional, morphological and
genetic level.29 A needle biopsy cannot represent the true picture of biomarker distribution in the
entire tumor or metastatic sites which could also have characteristics that differ from the primary
10

lesion. These limitations make needle biopsies highly impractical to assess the biomarker
distribution in the whole tumor or in different tumors in body.30 A non-invasive or minimally
invasive technique that can evaluate the levels and distribution of biomarker in the tumor is
needed to predict the therapeutic outcome of gem-based therapies that can aid physicians to
choose most appropriate therapy.
1.3.2

Imaging response to cancer therapies

Among minimally invasive techniques that are currently available, imaging has made
rapid advances in recent times and has become indispensable for cancer detection and measuring
response to cancer therapies.31-33 These imaging modalities include optoacoustic imaging,
sonography, magnetic resonance imaging (MRI), computerized tomography (CT), positron
emission tomography (PET) and single-photon emission computed tomography (SPECT).
Imaging offers a non-invasive, rapid and often quantifiable methods to detect the anatomy and
physiology of various biological process in real-time.33
Rudin and Weissleder compared molecular imaging methods and critically analyzed the
advantages and disadvantages of PET compared to other imaging techniques.34 The advantages
of PET have been reviewed comprehensively elsewhere as well.35, 36 Some advantages are that:
1) PET is quantifiable. The amount of PET tracer can be quantified as activity per volume of
tissue, which can be further translated to the mass of tracer accumulation in the tissue. 2) PET
requires only a miniscule amount of radioactive ligands to obtain good quality images because of
its high sensitivity. For example, a typical dose of fluorine-18 labeled fluorodeoxyglucose (2deoxy-2-[18F]fluoroglucose [18F]FDG), the most commonly used PET imaging agent to detect
tumors, is 370 MBq or 10 mCi, which is equivalent of 5.85 picomoles of fluorine-18 atoms or
1.05 ng of [18F]FDG 3) PET has moderate spatial resolution. Typical clinical PET machines can
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have a special resolution of 6-8 mm at best37 and the preclinical scanners can attain a resolution
of around 1-2 mm. As a result, the total amount of time to image the entire human body is low
and typically takes around 10 min.35 3) PET can detect signal from deep tissues. Unlike
optoacoustic imaging and sonography where the detection of the signal is limited by the depth of
tissue, PET can detect the signals from deep within the body. 4) Dynamic real time imaging PET
can detect signal from a source over a period of time which can greatly help in following the
pharmacokinetics of drug or drug like molecules over time, giving both spatial and temporal
information.
Such advantages over other imaging techniques have led to the development of novel PET
response criteria in solid tumors, PERCIST, which evaluates qualitative and quantitative
approaches to metabolic tumor response assessment with [18F]FDG.38 Furthermore, combining
techniques such as CT or MRI with PET, PET/CT and PET/MRI are becoming major imaging
techniques in the field of imaging to diagnose cancers and to study disease progression after
treatment.39 While PET offers many advantages, the technology is still expensive, has a very high
cost of operation and relies on radioactive molecules that are difficult to produce locally and are
widely misunderstood by the public.
1.3.3

Positron emission tomography (PET)

While radioactive decay of elements by emitting positrons was well known in 1950’s, it
took another 25 years for their utility in imaging to be realized and it was only in 1975 that
positrons were successfully used for imaging.40,

41

Despite being a relatively new imaging

modality, it has gained a huge popularity in the imaging community because of its high sensitivity,
use of picomolar tracer concentrations and ability to quantify the accumulation of tracer in real
time.34, 42
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PET exploits the properties of unstable radioactive isotopes that have higher number of
protons than neutrons in the atom’s nucleus. As the unstable isotopes undergo nuclear decay to
become stable, they emit a positron (β+), an antimatter of electron (e-) and an electron neutrino
(ve). A positron has identical properties to an electron except that it has an opposite positive charge.
When the emitted positron encounters an electron in its vicinity, it promptly undergoes mutual
annihilation and emits two gamma-rays travelling in approximately opposite directions. Detectors
placed precisely in a ring around the source can detect the origin of gamma rays within few mm
along the straight line by measuring nearly simultaneously (coincidence ~ 6-12 ns). Multiple
detections over the time increases the accuracy of origin of the gamma rays and helps in
mathematically recreating the 3D image of source using complex reconstruction algorithms in
computing systems (Figure 1.4.).
PET imaging has become more sophisticated with advances in detection methods such as
time-of-flight which can detect gamma coincidences within 3 nanosecond intervals and detect the
exact origin of the gamma radiation. Improving coincidence detection reduces noise from random
gamma incidences.
One significant advantage of PET over other imaging modalities for chemists is the
availability of organic PET radionuclides such as carbon-11, nitrogen-13, oxygen-15, fluorine-18,
bromine-75/76 and iodine-124, which enables the synthesis of radioactive equivalents of
biologically active compounds (Table 1.1.).
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Figure 1.4. The principle of PET showing the annihilation process of an emitted positron with
an electron using the PET probe [124I]FIAC as an example. Two anti-parallel 511 keV γ gamma
rays emitted from the point of annihilation are detected by circular detectors. The coincidences
are detected, processed by a computed to generated PET images as shown.

Table 1.1. List of positron emitting radioisotopes highlighting the isotopes amenable to organic
synthesis
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Researchers have taken the advantage of the quantitative nature of PET to predict the
amount of radiotracer uptake in the target organs. For example, the response to endocrine
treatment in breast cancer can be evaluated by imaging estrogen receptor expression using
[18F]fluoroestradiol (Figure 1.5).43, 44 Meanwhile, our lab has applied the concept of using PET
imaging as a pharmacokinetic marker of Hsp90 inhibitor drug PU-H71 (Fig 1.5).45, 46 Based on
the pharmacokinetic profile elucidated by the radioactive analog [124I]PU‐H71, PU-H71
underwent successful clinical trials and a first-in-human trial.47, 48

Figure 1.5. [18F]Fluoroestradiol and [124I]PU-H71

While PET has several advantages, it has its own drawbacks. Partial Volume Effect
(PVE) is one such limitation observed in PET and other biological imaging modalities as SPECT
and MRI. PVE leads to loss of apparent activity in small objects because of the finite resolution of
the imaging system and image sampling techniques employed currently.49 For example, in a
spherical lesion, the measured activity concentration is an average of 30% of the actual activity
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and a maximum of 60% of actual activity when the diameter of lesion is 1.5 times the spatial
resolution of the PET scanner at full width half maximum (FWHM, characteristic of PET
detectors.) A minimum lesion diameter of >4 times of FWHM is required for an accurate
representation of lesion within 5% of the actual activity in the lesion.50 The effects of PVE are
exacerbated by the shape of the tumors and activity in the surrounding tissues as well. There are
various methods that are proposed to reduce the errors attributed to PVE including applying
recovery coefficients or matrices during reconstruction and by applying modeling methods among
many.49
In the ways described above, PET is highly informational. An appropriate PET imagingbased biomarker that can the predict response of PaCa patients to gem therapy non-invasively
could dramatically improve the management of the disease with gem. Biomarker based diagnostics
that improve PaCa chemotherapy are lacking and are gravely needed, given the dismal prognosis
of PaCa and variable and poor response to treatment with gem.
1.3.4

The challenges to developing PET active gemcitabine

For molecules such as gem that contain natural isotope of fluorine (fluorine-19,

19

F),

labeling with PET active fluorine-18 (18F) is generally the first approach considered to make a
PET active equivalent. Substituting fluorine-18 with fluorine does not alter the properties of the
molecule because fluorine-18 and fluorine-19 are chemically equivalent.51
While nucleophilic mono-fluorinations with fluorine-19 using leaving groups are a wellknown class of fluorination reactions, fluorine-18 radiolabeling is challenging.52 Unlike 19F, most
readily available form of 18F is in heavy water, which considerably reduces the nucleophilicity of
already poor nucleophile.53 Various methods to increase the nucleophilicity have been developed
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and are in use to mitigate the nucleophilicity challenges. Secondly, the concentration of

18

F is

generally in large sub-stoichiometry with respect to precursor and requires higher temperatures
for carrying out such radiolabeling. High reaction temperatures required to perform these
transformations make it difficult to control competing elimination reactions. Thirdly, while the
109.7 min half-life is ideally long for imaging, it imposes time-constraints that limits the types of
reactions and the number of purification steps. If these parameters are not optimized, it requires
radiochemists to start the reactions with a high amount of radioactivity potentially exposing them
to high doses of radiation. Consequently late-stage fluorinations are preferred to early-stage
fluorinations, for which the precursors are few. Geminal-diflourinations have traditionally been a
challenge.
Despite such challenges, attempts were made to synthesize

18

F-labeled gemcitabine via

protected intermediate (19) using late stage fluorinations (Scheme A.1.1.).54 While protected
penultimate product 19 was reported to be synthesized in 0.2-0.3% (n=3) radiochemical yields,
further deprotection efforts have not been reported. It must be noted that these results were
published as part of doctoral thesis in 2015 however to date that data has not been published in
any peer-reviewed publications. Geminal-diflourinations using late stage precursor (14) have
been achieved using 19F in nucleoside analog 3′,3′-difluoro-3′-deoxythymidine.55 Similar methods
were used for geminal difluorinations and were performed on a 2′-ketone precursor (14) reported
previously in the literature.56 Other strategies of introducing

18

F using fluorine-18 labeled

diethylaminosulfur trifluoride (18F-DAST) are highly impractical because of substantial side
product formation due to elimination reaction and instability of DAST (17) under the harsh
reaction conditions required for fluorinations.57-59 Currently, there is no evidence in literature of
a germinal difluorination on gemcitabine or its cytosine analogs.
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Carbon-14 analogs of gem were synthesized and are readily available today. The synthetic
methods employed to synthesize C-14 gem could be translated to synthesize PET active carbon11 (11C) labeled gemcitabine.56, 60 However, limited availability, inefficient reaction conditions
and extremely short half-life of

11

C (20.33 min) makes it highly impractical to synthesize and

image with 11C-lableled gem in a meaningful time frame.
Given the challenges to radiolabel gem with PET active isotopes of naturally occurring
elements in the molecule, probing chemically similar molecules that could be radiolabeled with
PET active isotopes is a viable option. PET active molecules that undergo similar metabolic
pathway as gem could be of great value as indirect means of understanding gem kinetics and can
help differentiate responders from non-responders.

1.3.5

PET probes for nucleotide salvage metabolism

Given the challenges in making a chemically identical PET active gem, PET tracers
that bear structural resemblance to gem have been previously explored. One such molecule 1-(2′deoxy-2′-[18F]fluoro--D-(arabinofuranosyl)cytosine ([18F]FAC, 21) has been extensively studied
by Radu’s group at UCLA, to assess its ability to non-invasively predict tumor response to gem
using positron emission tomography.61 The effectiveness of [18F]FAC to detect tumor responses
was due to [18F]FAC being an efficient substrate for phosphorylation by deoxycytidine kinase
(dCK), which plays an important rate limiting step in the metabolic activation of gem. dCK is a
critical enzyme that is constitutively expressed in all cells at background levels but its expression
is significantly increased in lymphoid cells and many cancer cell types.62 In addition to
phosphorylation of dC, dCK catalyzes phosphorylation of other nucleosides such as
deoxyadenosine and deoxyguanosine,63 and indeed this function has been leveraged in the
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development of several nucleoside based prodrugs in current clinical use including gem (Figure
1.6.). Previous studies showed a high correlation between response to gem treatment in 8-tumors
of different origin grown subcutaneously in mice and protein levels of dCK.64 Consequently,
[18F]FAC PET was used to non-invasively image the levels of dCK in tumors as a surrogate marker
of response to gem. Our group demonstrated that [18F]FAC can act as a surrogate marker for
gemcitabine.65 Role of dCK in chemotherapy and its utility as a potential target to develop new
chemotherapeutics or imaging agents is further discussed in chapter 2 (Section 2.2).
These studies showed that [18F]FAC (21) was selectively retained in cells expressing dCK
versus cells deficient in dCK (Figure 1.6, Figure 1.7). [18F]FAC is a substrate for cytidine
deaminase (CDA) and underwent deamination as well. In efforts to identify a substrate specific
for dCK but not CDA, L-2′-deoxy-2′-[18F]fluoro-β-D-arabinofuranosylcytosine (L-[18F]FAC, 22)
and 1-(2′-deoxy-2′-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine (L-[18F]FMAC, 23) were
also synthesized.66 It was established that while the co-expression of CDA with dCK decreased
the uptake of [18F]FAC, it did not affect the uptake of L-[18F]FMAC (23). Recently, 2-chloro-2′deoxy-2′-[18F]fluoro-9-β-d-arabinofuranosyl-adenine ([18F]CFA, 24), another nucleoside analog
was also developed as a marker for dCK uptake and tested in humans as well.67
1.3.6

Development of longer-lived radiolabeled analogs of gem for PET
imaging

Despite the advances discussed above, 18F-labeled nucleosides have inherent limitations.
One of the major issues is the short half-life of fluorine-18 that precludes the measurement of long-
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Figure 1.6. Examples of PET active nucleoside analogs designed by Radu’s group for functional
imaging of nucleoside metabolism

Figure 1.7. a) [18F]FAC is selectively taken up in dCK overexpressing cell lines (dCK+) while
showing no uptake in the dCK knockdown (dCK-) cells61 b) [18F]FAC images obtained in a
patient with diffuse large B-cell lymphoma (LA)68. The PET signal can also be visualized in
bone (B), liver (L), kidney (K), Blaadder (B) and stomach (S). (Figures reporduced from Liang,
RE et. al.(2009) and Kim W. et. al. (2011))
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term pharmacokinetic studies over longer than two or three half-lives (6h). The biodistribution of
18

F-FAC, its L-isomer L-[18F]FAC (22) and L-[18F]FMAC (23) in humans, showed that the

biological half-lives of the radiolabeled nucleoside analogs exceeded the physical half-life of
fluorine-18.69 The biological half-life was calculated using an exponential fit of the activity in
organ as a function of time. Thus, a radiolabeled molecule whose biological half-life matches its
physical half-life could be of great value to better understand the complete kinetics of the molecule.
In addition to a mismatch between the physical and biological half-lives of radiolabeled
nucleoside analogs (FAC to [18F]FAC), there is a mismatch between the radioactive half-life of
fluorine-18 and the biological half-life of gem-TP, the active form of gem (gem-CTP to 18F). While
the pro-drug gem clears rapidly from the blood within 3h, it bio-active form gem-TP has a biphasic
elimination from leukemic cells with an α-half-life of 3.9 h and β-half-life of 16 h.6, 70 It has also
been noted that for short infusions (<70 min), the half-life of gem ranges from 30-90 min and for
long infusions (>70 min), the half-life is 4-10 h.71 Therefore, 109.7 min radiological half-life of
fluorine-18 cannot measure gem pharmacokinetics over periods of time longer than 4-5 hours, the
maximum reasonable time to follow flourine-18 in vivo via PET. This time-limit complicates
complete pharmacokinetic characterization using 18F PET imaging.
Therefore, it is necessary to develop a longer-lived analog of gem that can act as a surrogate
marker for gem allowing the complete pharmacokinetic evaluation. Among the available, longer
lived positron emitting radioisotopes, iodine-124 (t½ - 4.18 days) is the only isotope that could
potentially overcome previous limitations and is synthetically useful. Thus, we undertook the
development of iodine labeled gem analogs to enable studies aimed to determine which patients
could benefit from chemotherapy with gem in long term studies, the primary goal of this project.
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1.4

Iodine-124
1.4.1

Physical properties

Iodine-124 is one of the 37 radioactive isotopes of iodine that can be produced in a nuclear
reactor or in a cyclotron and only long-lived positron emitting radioisotope of iodine72. Along
with the positron emitting iodine-124, there are other isotopes of iodine used in the clinical settings
including iodine-131 (t½ - 8.02 days), iodine-123 (t½ - 13.3 h) and iodine-125 (t½ - 59.49 days).
Iodine-124 has been gaining increased attention as an isotope of interest in both basic and applied
research, because of increasing accessibility to medical low-energy cyclotrons and increasing
utility of PET diagnostics in medicine. Several review articles have discussed many important
aspects of iodine-124 that range from its production and physical properties to it its utility in
designing new radiopharmaceuticals.72-75
Iodine-124 decays to tellurium-124 following a very complex cascade of positron and
gamma emissions76. A simplified scheme indicating the relevant emissions - two positrons (β+1
and β+2) and high energy gamma emissions (γ1, γ2 and γ3) is shown in Figure 1.7. Despite the lack
of abundance of positrons in total decay emissions (percentage totaling 23%) and presence of high
energy gamma emissions (603, 723 and 1691 KeV), iodine-124 research has been gaining lot of
attention in recent years.
1.4.2

Radioiodination Chemistry of small molecules

One of the main advantages of using radioactive iodine (radioiodine) is that its chemistry
is very well understood. Comprehensive reviews on radioiodination chemistry using iodine-124
have been published as well.73, 77 Radioactive iodination is very similar to non-radioactive have
been published as well.73, 77 Radioactive iodination is very similar to non-radioactive iodination
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Figure 1.8. Simplified iodine-124 decay scheme illustrating relevant positron and gamma
emissions. Schema adapted from Pentlow et. al76

techniques used in traditional organic chemistry, albeit at much lower concentrations of
radioactive iodine available for synthesis compared to other reaction precursors. Another major
consideration in radioiodination reactions is the availability of limited oxidation forms of
radioiodine for synthetic reactions. While non-radioactive iodine can be purchased in various
forms such as iodine (I2, I0), sodium iodide (NaI, I-) and iodine monochloride (ICl, I+), radioactive
iodine is available only in the form of NaI (iodide, I- dissolved in dilute NaOH).
Radioactive iodinations can be mainly divided into direct iodinations and indirect
iodinations (such as using prosthetic groups) and both types of reactions are employed in general
laboratory settings. Direct radio-iodinations are preferred in the synthesis of small molecules to
23

make direct covalent bonds between the small molecule and radioactive iodine. Indirect
iodinations are employed in the synthesis of radioactive large molecules such as proteins,
antibodies and nanoparticles where the radioactive iodine containing synthon is conjugated to the
antibody or protein.
Direct radio-iodination reactions can be further classified into two major types electrophilic and nucleophilic. The most commonly used radio-iodination reactions are
electrophilic substitution that utilize various oxidizing agents that generate synthetic equivalents
of I+ in situ. The most commonly used oxidizing agents are N-chlorotoluenesulfonamide
(chloramines-T), iododbeadsTM, N-chlorosuccinamide (NCS) and 1,2,4,6-tetrachloro-3α,6αdiphenylglycouril (IodogenTM). Commonly employed electrophilic substitution reactions include
direct aromatic iodinations and destannylations (Scheme 1.2.). Recently other promising leaving
groups such as boronic esters using copper catalysts have been elucidated.78 The high yielding
non-carrier added electrophilic reactions are possible because of the highly selective cleavage of
weak sp2 bonds formed with carbon (Sn-C, B-C etc.). In addition to the weak sp2 bond,
electrophilic aromatic reactions are facilitated by the positive inductive effect between carbon and
the inorganic atom (Sn or B).
While C-I bond formation proceeds with, C-I bond are prone to rapid deiodination
because of its relative lower bond energy (240 kJ/mol). Moreover, it is well-known that aromatic
or sp2 hybridized carbon-iodine bonds are more stable than aliphatic C-I bonds. Consequently,
aromatic or vinylic C-I bonds are preferred which confer high metabolic stability towards
radioiodination in vivo.
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Scheme 1.2. Synthesis of [124I]PU-H71 under electrophilic conditions starting from stannane
precursor. Reagents and conditions: a) [124I]NaI, chloramine-T, 50 °C; b) 6M HCl, 50 °C

Nucleophilic substitutions are slower and require harsher reaction conditions compared to
electrophilic iodinations. Halogen exchange reactions are the most common nucleophilic method
for the introduction of iodine into organic molecules. Halex reactions generally require ammonium
sulfate or copper (II) salts.79 [131I]MIBG 59 (Scheme 1.3.), is a radiotherapeutic used to treat brain
tumors which was first synthesized by one such halogen exchange reaction. Later destannylation
reactions were also reported for the same reaction.80, 81

Scheme 1.3. Synthesis of meta-[131I]iodobenzylguanidine [131I]MIBG via an isotopic exchange
nucleophilic substitution
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Indirect radio-iodinations are employed when direct radioiodinations are either not feasible
or when introducing additional groups does not lead to loss of biological activity. These reactions
find most of their utility in radiolabeling proteins and antibodies. Indirect-radiolabeling is achieved
either by prosthetic groups such as Bolten-Hunter reagents or by conjugate radiolabeling methods.
Indirect radioiodinations have been elucidated in detail in comprehensive reviews82 and are not
considered useful for labeling small molecules because of the introduction of high degree of
structural variability.
1.4.3

Biodistribution of radioactive iodine

In the developmental stage of any new radiopharmaceutical, it is important to understand
the distribution of the free radioisotopes, should it be released metabolically from the radiotracer
in vivo. The normal biodistribution of radioisotope enables the scientists to rationally develop PET
imaging agents for a specific need. For example, free fluorine-18, residualizes in bones and is
therefore not suitable to for imaging a bone tumor or osteosarcoma (it is however useful in
detecting osteoblastic lesions). Moreover, knowing the normal distribution can help a physician to
differentiate between signal and noise when such novel molecules are used in clinical settings.
Luckily, the behavior of free iodine is very well understood because of it’s the utility of
radioiodine in variety of thyroid disorders and malignancies. Iodine-131 has been used clinically
for hyperthyroidism since early 1950s.83 Radioactive isotopes of iodine have found a widespread
use in medical use for humans, both as diagnostic tools and as a therapeutic agents, especially in
thyroid cancer.84, 85 Along with thyroid cancer and hyperthyroidism patients, distribution of free
radioactive iodine has been studied in healthy human volunteers with normal renal clearance as
well(Figure 1.9.).86,

87

Similar to natural iodine, iodine-127, radioactive isotopes of iodine

preferentially accumulated in thyroid. The uptake in salivary glands, stomach and intestines is
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minimal and there is a significant liver uptake. The absence of pancreatic uptake, and therefore the
absence of residualization of the free radioactive iodine in pancreas after its metabolism can help
us design better drugs containing radioactive iodine. Generally, for imaging, the thyroid uptake of
free radioiodine is competitively inhibited by pre-treating the patient with large excess of iodine
using iodine-excess diet and fluids.

a)

b)

Figure 1.9. a) whole body radioiodine scintigraphy images obtained at day 7 after an ablation
dose of 3700 MBq (100 mCi) iodine-131 in a patient with normal renal function. Residual
thyroid uptake together with moderate diffuse hepatic uptake and a faintly visible nasal uptake is
present. b) whole-body radioiodine images obtained at day 7 after 3700 MBq iodine-131
administration in a thyroid cancer patient undergoing hemodialysis. Significant bilateral parotid
and mild bilateral submandibular uptake together with a linear pattern of oral activity and local
nasal uptake is present. A prominent gastric uptake with minimal intestinal activity can be
observed. Hepatic activity is not visible. (Images reprinted from Aktas A et al. (2008,Licence
number: 4513870242440))
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1.4.4

Challenges and opportunities of using iodine-124 for PET imaging

Despite its favorable properties for the development of an ideal long-lived PET imaging
agent, iodine-124 has its inherent challenges as a radioisotope for PET imaging in particular, and
as a choice for radiolabeling in general. The first challenge is the high energies of the emitted
positrons. As elucidated in the decay scheme (Figure 1.8), the two positrons that are emitted (β+1
and β+2) have the energies of 1535 and 2138 keV. These energies are quite high when compared
to other positron emitting isotopes such as fluorine-18 (634 keV) and consequently they travel
farther distances in vivo before attenuation. As a comparison, while the emitted positron from
fluorine-18 has maximum range in water (Rmax) of 2.4 mm and mean range in water (Rmean) of 0.6
mm, iodine-124 has an Rmax of 10.0 mm and Rmean of 4.4 mm.88 As a result, the image resolution
is limited and often leads to imprecision in the exact location and boundaries of the target (such as
tumors) in vivo. This further leads to decreased recovery and underestimation of iodine-124
concentration in smaller targets, referred to as partial volume effect (PVE, Section 1.3.3).89
The limitations in image resolution are further complicated by 603 the keV gamma photons
that are accompanied with 60.5% of all decays (about 50% of all positron decays). Along with
lowering image resolution as result of false positive coincidences (Figure 1.10.), high-energy
positrons and accompanying gammas also increase the radiation dose on patients. While a true
coincidence (Figure 1.10.a) occurs when both photons from the annihilation event are detected by
detectors with no concurrent events, false positive coincidences are caused by scattered or random
coincidences as shown in Figure 1.10.b and c respectively. While random coincidences (arising
from two photons not arising from same annihilation event) and scattered coincidences (arising
from photons undergoing Compton scattering prior to detection) are common for most of the PET
active isotopes, multiple false positive incidences are exacerbated for Iodine-124 because of
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multiple gamma rays occurring because of the complex decay scheme. Multiple coincidences
occur when more than two photons are detected in different detectors concurrently (within the
dead-time of the detectors) which leads to rejection of such events by the PET processing units.

Figure 1.10. a) True b) scattered and c) random coincidences are registered in the PET detector
ring. Scattered and random coincidences, however, may be assigned to wrong line of response
(LOR) indicated in dotted blue lines.

In a simplified decay scheme of iodine-124 (Figure 1.8), only 23% of all decay events
result in positron emission. Such low abundance of positrons results in a long imaging time.
Increasing the dose of iodine-124 to lower the imaging time is not advisable, as it proportionally
increases the radiation dose to the patient. Radiation dose to the organs is accentuated by long halflife of iodine-124 which increases the residence time of radioactivity in the human body.
Moreover, iodine-124 is expensive to produce because of the high cost of enriched tellurium,
which drives up the overall cost of PET imaging.
While labeling molecules with radioactive iodine is highly desirable for the molecules
whose cold analogs naturally have iodine, the introduction of iodine into molecules whose natural
analogs do not contain any iodine poses its own challenges.90, 91 Two aspects of the carbon-iodine
bond must be considered - bond dissociation energy and bond length. While the bond dissociation
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energies are responsible for stability of molecule in vivo, bond lengths play an important role in
the activity of the molecule by interfering with the sterics of binding pocket in the target. C-I bond
is twice as long as a C-H bond (214 pm vs 109 pm), which lead to steric interactions generally
decreasing, if not completely preventing the binding of iodinated analog. While the bond length is
almost double, the C-I bond energy is almost the half of C-H bond (216 kJ/mol vs 413 kJ/mol).
Such weak bond energy leads to easy dissociation of iodine from the drug molecule in vivo,
especially in molecules containing activated aromatic rings. Rapid deiodination precludes our
ability to track the pharmacokinetics of a radiolabeled molecule by imaging and represents a
problem of its own in PET imaging, offsetting the advantages of long half-lives of the isotopes
used in labeling molecules.
Despite these challenges, recent technological improvements make iodine-124 an excellent
isotope for PET labeling. These include: 1) the advances in PET reconstruction protocols to
eliminate the effects of high energy gamma coincidences which facilitate obtaining high resolution
images in short imaging times92 2) well-investigated chemistry of iodine, and 3) long half-life of
I-124 (4.18 days) which is appropriate to study the drug kinetics non-invasively for longer time
frames.93 Additionally, availability of alternate forms of radioactive iodine such as iodine-123,
iodine-125 and iodine-131, enables the development of radiotherapeutics. As of June 2018, there
are at least 44 active clinical trials listed on clinicaltrials.gov website. Of these trials, majority of
active trials are testing either free iodine-124 or iodine-124 labeled antibodies. Only four of the
active trials are based on small molecules, namely heat shock protein 90 (Hsp90) inhibitor
[124I]PUH71,

meta-[124I]iodobenzylguanidine [124I]MIBG,

phospholipid ether analogue

[124I]NM404 and iodine-124 labeled fialuridine [124I]FIAU. The paucity of iodine-124 labeled
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small molecules highlights the developmental potential in the area of iodine-124 labeled molecules
for disease diagnosis and clinical management using PET imaging.
1.5

Summary

Gemcitabine is a mainstay in pancreatic cancer treatment but is effective in only a small
sub-population of patients (~30%). Despite the use of gem as first line of treatment for PaCa, there
is no a priori way to know which patient will respond to gem therapy. Distinguishing responders
and non-responders as early as possible will greatly aid in patient selection and dose selection and
provide alternative therapies to non-responders, greatly aiding in choosing best therapy suitable
for a particular patient. Functional, quantitative molecular imaging with PET is a powerful
paradigm in PaCa management. The availability of PET active isotope of iodine and fluorine, I124 and F-18, greatly aids in the synthesis of PET active gem analogs that model gem
pharmacology accurately. In the metabolic pathway of gem, deoxycytidine kinase (dCK) is an
important rate-limiting enzyme that is necessary to convert gem into its cytotoxic derivative.
Therefore, levels of dCK in tumors could aid in predicting the drug’s efficacy (i.e. cellular
conversion of prodrug into its active form) to treat cancers and predict patient response to therapy.
Previous research explored fluorine-18 labeled analogs of gemcitabine. Based on the results of
those studies, we anticipate that gem analogs labeled with longer lived isotope such as iodine-124
will yield a wealth of complementary information including aiding us in determining the
distribution and accumulation of drug in tissue or tumor over longer periods of time which can in
turn help us differentiating the responders from non-responders in a rational way. Given the tools
of chemistry and knowledge of gem’s pharmacology in this chapter, future chapters will focus on
design, development and evaluation of iodine-124 labeled gem analogs in laboratory models that
mimic response to gem treatment.
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CHAPTER 2: DESIGN AND SYNTHESIS OF 5-IODO-SUBSTITUTED
NUCLEOSIDE ANALOGS
2.1

Introduction

In the previous chapter we proposed the development of iodine-124 labeled gem analogs
as new PET imaging agents with a potential to stratify the responsiveness of pancreatic tumor
patients to gem therapy. A fundamental aspect in the design of functional gem analogs is to assure
their ability to retain the affinity to the target after the introduction of the iodine-124 group. In this
direction, it is important to understand the interactions of the proposed new molecules with their
target and to determine the degree of change in those interactions with respect to gem or dC. In
the previous chapter, it was observed that dCK is one of the key enzymes that determine the
effectiveness of nucleoside analogs as chemotherapeutic drugs because of its key role as a ratelimiting enzyme in the nucleoside metabolic pathway. Therefore, in this chapter we will further
explore the role of dCK as a target for the development of new nucleoside analogs. In particular,
we analyze the interactions between dCK and the proposed new set of iodine-124-based PET
probes by performing in silico protein-ligand interaction-modeling using software from
Schrödinger and describe the chemical synthesis of those molecules.
2.2

dCK as a target for developing new PET active gem analogs

Deoxycytidine kinase (dCK) is a 260-amino acid enzyme with a calculated mass of
30.5 kD, essential for the phosphorylation of deoxycytidine (dC, 2) and other nucleosides, such as
deoxyadenosine (dA), deoxyguanosine (dG). dCK also phosphorylates many nucleoside analogs
widely used as chemotherapeutic agents, including ara-C, clofarabine, cladribine, troxacitabine
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and fludarabine.1 In addition to phosphorylating the chemotherapeutics, dCK phosphorylates antiviral drugs such as ddC and 3TC as well, that are used in the treatment of HIV infection. The
phosphorylation of nucleosides or nucleoside analogs (pro-drugs) is the rate-limiting step for
retaining the pro-drugs inside the cell after their cytoplasmic transport into the cell by nucleoside
transporters located in the plasma membrane. The “trapping” of the pro-drugs occurs because of
the net negative charge of phosphorylated product at the physiological pH and any molecule with
a net charge (negative or positive) cannot cross the cell membrane. The monophosphorylated
deoxy-nucleotides are then substrates for double and triple phosphorylation by associated enzymes
to serve as precursors for DNA synthesis by incorporation into the DNA backbone.
The role of dCK in chemotherapy is widely and actively studied and it has been shown that
dCK has special application in cancer therapy mainly because of its overexpression in cancer
cells.2 It is postulated that the increased levels of dCK in cancer cells occurs because of their
constant activated state due to the high rate of cell division. This feature makes dCK an ideal target
with special application for the development of molecules with chemotherapeutic activity and/or
diagnostic potential
Various retrospective studies have evaluated the levels of dCK expression in tumor
samples collected during surgery and correlated the levels to the survival of patients who
underwent gem therapy. Among the patients (n=243) who received gem therapy after a surgery,
there was a high correlation (p = 0.012) between the survival time and the level of dCK and human
equilibrative nucleoside transporters (hENT) but not ribonucleotide reductase (RRM1) as analyzed
by immunohistology.3 In another study involving a group of 44 patients, a significant difference
in the overall survival was observed between patient with tumors expressing low and high dCK
levels also evaluated via immunohistology (p<0.009).4 The patients were stratified into low and
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high dCK immunogroups based on staining intensity. (Low for negative to +1 level dCK staining
and high for 2-3+ dCK staining intensity.) Patients having low dCK levels had an overall survival
of 28 months versus 40 months for high dCK levels. Gem treated patients with tumors expressing
higher levels of dCK had significantly higher survival rates compared with those with tumors
expressing low levels of dCK. Similar results were also observed in models of human tumor grown
in mice. The sensitivity to gemcitabine was clearly related to the level of dCK activity and protein
expression, but not to dCK mRNA levels.5
Based on these results, it was hypothesized that the levels of dCK protein and its enzymatic
activity in the tumors differentiate patients into responders vs. non-responders to gemcitabine
treatment. In this perspective, PET probes that allow the non-invasive imaging of dCK levels in
the tumor have the potential to identify cancer patients who are likely to benefit from the treatment
with gem and/or other nucleoside based pro-drugs that require dCK for their activation.
2.2.1

Crystal structure of deoxycytidine kinase (dCK)

dCK in complex with Ara-C, dC and gem was crystallized by Sabini et. al.1
Molecular modeling was performed on the gem-ADP-Mg complex of dCK (Protein Data Bank
accession code 1P62) and the critical hydrogen bonds were chosen based on the findings within
the manuscript. The hydrogen bonds critical for the interaction between dCK and its substrates
were selected in the manuscript based on the conserved structural homology of the amino acids
between human dCK, human dGK (deoxyguanosine kinase), dNK (Drosophila melanogaster
nucleoside kinase) and hTK2 (human thymidine kinase 2) and their ability and efficiency to
phosphorylate various cellular nucleosides. These analyses revealed a high degree of structural
homology (50 - 70%) amongst the related enzymes but also pointed out the existence of minor
differences in the amino acid sequence that have a major impact on substrate selection and kinetic
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rates. Amongst those minor but functionally relevant differences in the protein sequence, the
critical amino acids are identified based on their presence in the binding pocket of the enzyme,
distance from various atoms on the bound substrate and their ability to act as hydrogen bond donors
or acceptors.
Among the hydrogen bonds between the substrate and the amino acids in dCK, the critical
pair of hydrogen bonds responsible for the substrate selectivity are (Figure 2.1.) – 1) H-bond
between Glu53 and 5′-H of 5′-hydroxyl group and 2) H-bond between Arg128 and 2′-arabino
substituent. Glu53 acts as a base in the phosphorylation by abstracting 5′-H on OH. Along with
forming a hydrogen bond with 5′-OH, it also bonds with Arg128, thus forming a long chain of
hydrogen bonding from 2′-arabino substituent to 5′-hydroxyl hydrogen through Arg128 and
Glu53. Strength of H-bonding between 2′-arabino substituent and Arg128 affects the rate of
phosphorylation of the substrate. It was suggested that stronger H-bonding with Arg128 because
of 2′-fluoro or 2′-hydroxyl was responsible for faster kinetics of gem and ara-C respectively,
compared to dC where both arabinose and ribose substituents on 2′-postion of sugar are hydrogens.
The hydrogen bonding between Asp133 and primary 4-amino group (-NH2) on cytosine is
responsible for the inability of dCK to phosphorylate thymidine and deoxyuridine, in which a
ketone (C=O) group replaces the 4-amino position. While it is suggested that steric clash between
Arg104 and 5-methyl group in thymine is responsible for discrimination by dCK against 5′substituted pyrimidines, the ability of dCK to catalyze the phosphorylation of bulkier purines,
deoxyguanosine (dG) and deoxyadenosine (dA), suggest that the modifications on ring could still
retain substrate specificity. Based on the research group’s (Sabini et. al.) inability to crystallize
dCK bound to 2′,3′-dideoxycytosine, it was suggested that hydrogen bonds between Glu197 and
2′-hydroxyl and Tyr86 and 2′-ribo-sustitutent are responsible for the stability of the complex and
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hence responsible for overall efficiency of phosphorylation. Based on these observations, the
above-mentioned hydrogen bonds were used to generate the receptor grid and the modeling was
performed using Schrödinger software.

Figure 2.1. Major interaction of nucleoside analogs with dCK binding pocket. All distances are in
Å. (Image reproduced from Sabini et al. Printed with reprint permission license number
4380981342248 )
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2.3

Results and discussion
2.3.1

Designing iodine labeled gemcitabine analogs

Determining the salient features of enzyme-drug interactions that affect the drug’s
pharmacokinetics and its ability to phosphorylate various substrates is critical for the
design of novel ligands that conserve such basic essential interactions. It was observed that
the 5- and 6-positions on the cytosine moiety do not form any critical hydrogen bonds with
any amino acid residues in the enzyme. While the iodination reactions on 6-position are
not well understood, the 5-position (ortho to free amine) is suitable for electrophilic
aromatic iodination. Ease of iodination at 5-position of cytosine opens the possibility of
introducing modification without compromising the overall dCK-nucleoside interaction.
Based on their structural resemblance to gem and dC, the three molecules 2′-fluoro2′-deoxy-1-β-D-arabinofuranosyl-5-iodocytosine (FIAC, 25, Figure 2.2), 2′-Fluoro-2′deoxy-1-β–D-ribofuranosyl-5-iodocytosine (FIRC, 26, Figure 2.2) and 2′,2′,-difluoro2′,2′-dideoxy-1-β–D-furanosyl-5-iodo-cytosine (Igem, 27, Figure 2.2) were envisioned.
While all three molecules contain the same 5-iodinated cytosine, the substitutions on 2′carbon of the sugar moiety are different. As shown in the figure, while FIRC has fluorine
at 2′ position in ribose position (up and syn to cytosine), FIAC has fluorine at 2′ position
in arabinose position (down and anti to cytosine) and Igem has both the 2′-positions (riboand arabino-) substituted by fluorines.
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Figure 2.2. a) Docking score of various gem analogs b) Energy optimized images showing the 3dimensional orientation of gem analogs generated by Schrödinger’s ligprep suite used for
generating docking scores by Schrödinger’s glide suite.

The modeling studies showed good docking scores of proposed iodinated analogs when
compared to docking scores of natural substrate dC and the drug molecule gem (lower negative
docking scores represent a better fit.) Based on the docking studies, dC is the best substrate for
dCK, followed by gem, FIAC, FIRC and IGem. Sabini et. al. reported that gem has roughly fourfold higher enzymatic efficiency (kcat/Km) than dC for dCK (10-fold increase in kcat but only a
slight increase in Km). These results are confounding, and it has to be noted that docking scores
neither represent nor correspond to the free-energy calculations of protein-ligand interactions.
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Moreover, mere good scores do not guarantee the ability of a molecule to be better substrates for
enzyme in vivo, as the behavior of drugs in vivo is influenced by various other factors along with
the drug’s ability to be phosphorylated. Nevertheless, molecular modeling studies provide a good
rationale to synthesize the predicted molecules.
Based on the modeling studies and the feasibility to introduce iodine at 5-position, we
concentrated our efforts on synthesizing and evaluating the abovementioned gem analogs as
biomarkers of gem response.
2.3.2

Synthesis of non-radioactive 5-iodo-substituted gemcitabine analogs

5-iodo-substituted nucleoside analogs have played a very important role as precursors for
further substitutions to synthesize various 5-substituted nucleoside analogs. Iodine is a very good
leaving group and facilitates further substitution reactions. Carbon-iodine bond formations are
very well-known reactions that have been extensively reviewed in the literature. Among the
iodination reactions available, electrophilic iodinations are the most useful reactions for aromatic
rings with or without heteroatom. Various iodinating agents for nucleosides are known in the
literature. These include barium iodide, chloramine-T and N-iododsuccinimide.6 Nucleophilic
aromatic substitution reactions such as aromatic Finkelstein represent alternative strategies in case
that direct iodination is not possible.7
2′-Fluoro-2′-deoxy-1-β–D-ribofuranosyl-5-iodocytosine (FIRC, 26, Scheme 2.1) was
synthesized using iodine monochloride (ICl) as the source of iodine.
FIRC was isolated in ~25 % yield (19 mg) as a pale yellow crystalline solid.
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Iodinations using ICl are relatively fast reactions and generally proceed at very mild
conditions. In our hands, reactions did not proceed to completion after repeated attempts to stir the
reaction overnight at room-temperature. The reaction proceeds to completion after heating in
microwave for 20 min and the product yields were low.

Scheme 2.1. Synthesis of 2′-Fluoro-2′-deoxy-1-β–D-ribofuranosyl-5-iodocytosine (FIRC, 26)

2′,2′-difluoro-2′,2′-dideoxy-1-β–D-furanosyl-5-iodo-cytosine (Igem, 27, Scheme 2.2) was
synthesized using the reaction conditions used to synthesize FIRC. IGem was isolated in ~ 23 %
(24 mg) as a pale yellow crystalline solid
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Scheme 2.2. Synthesis of 2′,2′-difluoro-2′,2′-dideoxy-1-β–D-furanosyl-5-iodo-cytosine (Igem,
27)

2′-Fluoro-2′-deoxy-1-β-D-arabinofuranosyl-5-iodocytosine (FIAC, 25 Scheme 2.3) was
previously synthesized using iodic acid (HIO3) and iodine in carabontetrachloride (CCl4); and
acetic acid was used as a very mild oxidizing agent.8 After successful synthesis of FIRC and IGem,
similar iodination conditions were employed in the synthesis of FIAC (Scheme 2.4).

Scheme 2.3: Synthesis of 2′-Fluoro-2′-deoxy-1-β-D-arabinofuranosyl-5-iodocytosine (FIAC, 25)
reported by Watanabe et al.

FIAC was isolated in~16 % (12 mg) yields as a pale yellow crystalline solid.
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Scheme 2.4: Synthesis of 2′-Fluoro-2′-deoxy-1-β-D-arabinofuranosyl-5-iodocytosine (FIAC, 25)

While FIRC and Igem precipitated when some water was added to the reaction mixture
concentrate after removal of methanol under pressure, FIAC did not precipitate. The amount of
precursor available for reaction was limited by the cost of the precursor. The products were not
needed for their assay as a chemotherapeutic and were only needed to assess the identity of the
radioactive (hot) analogs.
Purity of the cold products is of utmost importance because of their utility in confirming
the identity and the specific activity of the radioactive analogs. It is important for the cold
compound to have a single peak on HPLC and to be devoid of any other impurities. Such impurities
greatly alter the specific activity of the radioactive analogs.
2.3.3

Synthesis of radioactive 5-iodo-substituted gemcitabine analogs

While it is ideal to synthesize the radioiodinated compounds in similar reaction conditions
that are used to synthesize the non-radioactive (cold) compounds, the availability of radioiodine
in the form of iodide alone (I- in NaOH) limits the utilization of similar reaction conditions. Instead,
electrophilic I+ is generated in situ using oxidizing agents such as chloramine-T.
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Electrophilic iodinations using chloramines-T are well known in literature and were
utilized to synthesize 2′-Fluoro-2′-deoxy-1-β–D-ribofuranosyl-5-[131I]iodocytosine ([131I FIRC,
31, Scheme 2.5).
[131]FIRC was synthesized in 55-60 % radiochemical yield isolated on HPLC (Figure 2.3.)
Specific activity of [131]FIRC was not determined.
Product identity was confirmed by co-injecting non-radioactive FIRC with the radioactive
fraction onto HPLC and verifying that both the non-radioactive (UV signal) and radioactive analog
(bioscan signal) had same retention time. Slight delay in the radioactive peak is due to fact that the
radioactive detector is placed in series after the UV detector and the delay time of 0.7 min is the
time taken by the sample to reach the radioactive detector from the UV detector.
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Scheme 2.5 Synthesis of 2′-Fluoro-2′-deoxy-1-β–D-ribofuranosyl-5-[131I]iodocytosine
([131I]FIRC)

Figure 2.3 a) HPLC chromatogram showing the purification of [131I]FIRC using a semi
preparative HPLC system. Blue line: radioactive signal from radioactive detector Red line: UV
signal from UV detector @ 254 nm. b) Quality control analysis of [131I]FIRC with analytical
HPLC system showing coinjection of purified [131I]FIRC from preparatory column and nonradioactive FRC

As mentioned earlier, because of the low concentrations of the radioisotopes in the reaction
mixture (and hence the products), conventional chemical characterization of the product using
NMR and mass spec was not feasible. Moreover, eventual radioactive contamination of the
instruments represents a major hazard in case of an accident. For this reason, we used a HPLC
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apparatus dedicated to the purifications of radioactive material in a shielded ventilated hood. The
reaction mixture was quenched with water and injected into the HPLC system. All the radioactive
fractions were collected and the radioactivity in each sample was measured to isolate the
radioactive product, determine the efficiency of the reactions and the amount of free iodine and
byproducts in the reaction mixture. The sample containing the radioactive analog was injected into
the HPLC system to determine the purity of the collected fraction. Once the purity was confirmed,
the fraction was spiked with cold pure compound that was synthesized earlier and injected into the
HPLC. The identity of the product was confirmed by the co-elution of the radioactive analog with
the non-radioactive analog as determined by the radiodetector and the UV tracer. The pure
radioactive fractions were left in the HPLC eluent (8% acetonitrile in water containing 0.1%TFA)
and periodically injected into HPLC to study the stability of the product.
2′,2′,-difluoro-2′,2′-dideoxy-1-β–D-furanosyl-5-iodo-cytosine ([131I]IGem, 32, Scheme
2.6) was synthesized by slightly modifying previously literature.9 [131I]IGem was synthesized in
45-40 % radiochemical yield isolated on HPLC (Figure 2.4) with specific activity between 2.3
Ci/mmol as calculated by the AUC of UV absorption of [131]FIAC at 254 nm. The specific activity
of 2.3 Ci/mmol is quite low. Previously in our lab, iodinations using tin-precursors yielded [124I]PU-H71 with a specific activity in the range of 280-980 Ci/mmol.10, 11 Repeated attempts were
made to rule out the usual discrepancies in estimating specific activities such as synthesizing pure
cold standard, increasing the accuracy of weighing the cold standard and calibrating the UV
absorption curve at very low concentrations. Despite such efforts and high solubility of iodinated
products, the specific activity of the radioactive products could not be increased. A possible
alternative to synthesize tin precursors was unsuccessful.

45

Scheme 2.6: Synthesis of [131I]IGem

Figure 2.4. a) HPLC chromatogram showing the purification of [131I]IGem using a semi
preparative HPLC system. Blue line: radioactive signal from radioactive detector Red line: UV
signal from UV detector @ 254 nm. b) Quality control analysis of [131I]IGem with analytical
HPLC system showing coinjection of purified [131I]IGem from preparatory column and nonradioactive FAC

Similarly, [131I]FIAC was synthesized in 40-50 % radiochemical yield isolated on HPLC
(Scheme 2.7 and Figure 2.5 ) with specific activity between 35-40 Ci/mmol as calculated by the
AUC of UV absorption [131I]FIAC at 254 nm (Scheme 11).
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Scheme 2.7. Synthesis of [131I]FIAC

Figure 2.5. a) HPLC chromatogram showing the purification of [131I]FIAC using a semi
preparative HPLC system. Blue line: radioactive signal from radioactive detector Red line: UV
signal from UV detector @ 254 nm. b) Quality control analysis of [131I]FIAC with analytical
HPLC system showing coinjection of purified [131I]FIAC from preparatory column and nonradioactive FAC

While I-124 labeled gem analogs are the desired PET active tracers, the reaction conditions
were optimized using iodine-131 since it is relative inexpensive and has longer half-life than
iodine-124. While there was still some free radioactive iodide at the end of 20 min of heating,
further heating of the reaction resulted in the generation of unknown non-polar byproducts and
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which increased with reaction time without overall improvement in the product yield. Thus, 20
min heating time was determined to be the optimal condition, minimizing the generation of
byproducts while yielding the highest amounts of the product.
Iodination of dFdC was attempted using other oxidants such as ICl, iodogen and
chloramine-T. 4 μg of chloramine-T was found to be optimal for the reactions based on the
previous experience in our lab. Increasing or decreasing the amount of chloramine-T did not alter
the yields of the product. However, it was always important to use freshly made solution of
chloramine-T in acetic acid since pre-made solutions decreased the yields of the radioactive
product. Using iodine-131 the yields were reasonable (around 50% yields). For reasons beyond
our explanations, the older the iodine was, the better the yields were of the radiolabeled products.
Along with deionized water, we employed other solvent such as ethanol and methanol. Among
these solvents, the use of deionized water resulted in substantially higher yields.
2.4

Conclusion
Based on the in silico predictions, non-radioactive and radioactive iodine substituted gem

analogs were successfully synthesized, albeit in lower yields.

2.5

Experimental Section
2.5.1

General methods and materials:

All chemicals were obtained from commercial sources and used without further
purification. Gemcitabine was purchased from Ark Pharm, Inc, IL, USA (CAS: 95058-81-4, Cat#:
AK-23700) and FAC was purchased from Carbosynth, Berkshire, UK (CAS: 56632-83-8,
Product code: ND08343.) Chloramine-T was used as 2mg/mL solution in glacial acetic acid.
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Iodine monochloride (ICl) was purchased from Sigma Aldrich (Cat: 208221). Preparatory thin
layer chromatography was performed using 1000 µm silica gel plates (Analtech, cat 80086-350).
Carrier-free [131I]NaI in 0.1 N NaOH was obtained from Nuclear Diagnostic Products (Rockaway,
NJ, USA).
NMR spectra were recorded on a Bruker 500 MHz instrument. Chemical shifts are reported
in δ values in ppm downfield from TMS as the internal standard. Low resolution mass spectra
were obtained on a Waters Acquity Ultra Performance LC with electrospary ionization SQ
detector.
HPLC purification and analysis were performed on a Shimadzu HPLC system equipped
with a binary high-pressure gradient solvent delivery module LC 10A and SPD-20A UV dual
wavelength detector connected to a bioscan flow-count radio-HPLC detector system for gamma
detection. Crude products were purified and analyzed for purity on reversed phase C18 column
using Phenomenex® Gemini 5 µm, 250 x 4.6 mm 110 Å [00G-4435-E0]. Purification and analysis
were carried out using an isocratic solvent system of 8% acetonitrile in 0.1% trifluoroacetic acid
at a flow rate of 1 mL/min. Radioactivity was quantified with a WIZARDTM 3” 1480 gamma
counter (Perkin Elmer, Waltham, MA, USA) or a dose calibrator (Capintec® CRC-30BC, Ramsey,
NJ, USA).
2.5.2

Designing iodine labeled gemcitabine analogs

The envisioned molecules were subjected to docking studies using the previously generated
receptor grid in Schrödinger suite using the critical hydrogen bond interactions. Briefly, pdb file
1P62 was downloaded into Schrödinger’s ‘Maestro’ suite. The protein structure was automatically
processed using ‘protein preparation wizard’ which minimizes energy, adds missing hydrogens,
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assigns atomic charges and rectifies any abnormalities in protein. Various conformations of the
ligands to be docked were generated using ‘LigPrep’ tool. Using the previously generated receptor
grid and keeping the protein rigid, the ligands were systematically screened to obtain their docking
scores.
2.5.3

Synthesis of non-radioactive 5-iodo-substituted gemcitabine analogs

Detailed analytical and spectral data are included in the appendix
2.5.3.1

2′-Fluoro-2′-deoxy-1- β –D-ribofuranosyl-5-iodocytosine
(FIRC, 26)

FIRC was synthesized by adapting FIRC synthesis reported by Shi et. al 12 to microwave
synthesis. To a solution of 2′-fluoro-2′-deoxy-1-β–D-ribofuranosylcytosine (FRC) (50 mg, 0.04
mmol) in anhydrous methanol (5 mL) in a microwave vial, ICl (17.9 mg, 5 µL, 9 mmol) was added
and heated in a microwave for 30 min at 80 °C. The solvent was removed under reduced pressure
and residue was purified on preparatory TLC plate eluting with methanol/dichloromethane (1:10).
1

H NMR (500 MHz, DMSO-d6) δ 8.65 (s, 1H, H6), 8.36 (s, 1H, NH), 7.69 (s, 1H,NH),

5.84 (d, J = 16.4 Hz, 1H, H1′), 5.00 (d, J = 4.0 Hz, 1H, H2′), 4.89 (d, J = 4.0 Hz, 1H, H3′), 4.15
(ddd, J = 25.2, 8.7, 4.0 Hz, 1H, H4′), 3.92 (d, J = 8.5 Hz, 1H, OH5′), 3.86 (dd, J = 8.5 Hz, 5′) 3.61
(dd, J = 12.4, 2.3 Hz, 1H, OH5′). MS (MS+) m/z 394.14 [(M+Na+)]
2.5.3.2

2′,2′,-difluoro-2′,2′-dideoxy-1-β–D-furanosyl-5-iodocytosine (5Iodo-gemcitabine, IGem, 27)

IGem was synthesized using the reaction conditions used in the synthesis of FIRC. To a
solution of gemcitabine (Gem) (75 mg, 0.28 mmol) in anhydrous methanol (5 mL) in a microwave
vial, ICl (17.9 mg, 5 µL, 9 mmol) was added and heated in a microwave for 30 min at 80 °C. The
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solvent was removed under reduced pressure and residue was purified on preparatory TLC plate
eluting with methanol/dichloromethane (1:10).
1

H NMR (500 MHz, DMSO-d6) δ 8.21 (s, 1H, H6), 8.04 (s, 1H, NH), 6.83 (s, 1H, NH),

6.34 (s, 1H, OH3′), 6.06 (t, J = 7.4 Hz, 1H, H1′), 5.44 (s, 1H, OH5′), 4.19 (td, J = 12.9, 8.4 Hz,
1H, H3′), 3.88 – 3.70 (m, 2H, H5′), 3.63 (dd, J = 12.8, 3.0 Hz, 1H, H4′). MS (MS+) m/z
389.9[(M+H)+]
2′-Fluoro-2′-deoxy-1- β -D-arabinofuranosyl-5-iodocytosine

2.5.3.3

(FIAC, 25)
To a solution of 2′-Fluoro-2′-deoxy-1- β –D-arabinofuranosylcytosine (FAC) (50 mg, 0.04
mmol) in anhydrous methanol (5 mL) in a microwave vial, ICl (17.9 mg, 5 µL, 9 mmol) was
added and heated in a microwave for 30 min at 80 °C. The solvent was removed under reduced
pressure

and

residue

was

purified

on

preparatory

TLC

plate

eluting

with

methanol/dichloromethane (1:10).
1

H NMR (500 MHz, DMSO-d6) δ 8.05 (s, 1H, H6), 7.93, 6.72 (2s, 2H, NH2), 6.06 (dd, J

= 16.6, 4.0 Hz, 1H, H1′), 5.91 (s, 1H, OH-3′), 5.20 (s, 1H, OH-5′), 5.00 (ddd, J = 52.6, 4.0, 2.8 Hz,
1H, H2′), 4.20 (ddd, J = 20.1, 5.0, 2.7 Hz, 1H, H3′), 3.80 (q, J = 4.6 Hz, 1H, H4′), 3.71 – 3.52 (m,
2H, H5′) MS (MS+) m/z 372.14[(M+H)+)
2.5.4
2.5.4.1

Synthesis of radioactive 5-iodo-substituted gemcitabine analogs
2′-Fluoro-2′-deoxy-1- β –D-ribofuranosyl-5-[131I]iodocytosine
([131I]FIRC, 31)

To a solution of 100 µg of FRC dissolved in deionized water (100 µL) in an eppendorf
tube, 0.5 – 1 mCi of [131I]NaI (5-10 µL in 0.1 N NaOH) and chloramine-T (6µg, 2mg/mL solution
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in glacial acetic acid) were added and heated on a heating mantle at 95 °C for 20 min. The reaction
mixture was cooled to room temperature and 100 µL deionized water was added and purified on
HPLC. The eluent from the HPLC corresponding to radioactive peak was collected.
2.5.4.2
131I-IGem

5-[131I]Iodogemcitabine ([131I]IGem, 32)

was synthesized by slightly modifying previously literature (El-Kawy)9. To a

solution of 100 µg of gemcitabine dissolved in deionized water (100 µL) in an eppendorf tube, 0.5
– 1 mCi of [131I]NaI (5-10 µL in 0.1 N NaOH) and chloramine-T (6µg, 2mg/mL solution in glacial
acetic acid) were added and heated on a heating mantle at 95 °C for 20 min. The reaction mixture
was cooled to room temperature and 100 µL deionized water was added and purified on HPLC.
The eluent from the HPLC corresponding to radioactive peak was collected. Product identity was
confirmed by co-injecting non-radioactive IGem with the radioactive fraction onto HPLC.
2.5.4.3

2′-Fluoro-2′-deoxy-1- β -D-arabinofuranosyl-5[131I]iodocytosine ([131I]FIAC, 33)

To a solution of 100 µg of FAC dissolved in deionized water (100 µL) in an eppendorf
tube, 0.5 – 1 mCi of [131I]NaI (5-10 µL in 0.1 N NaOH) and chloramine-T (6µg, 2mg/mL solution
in glacial acetic acid) were added and heated on a heating mantle at 95 °C for 20 min. The reaction
mixture was cooled to room temperature and 100 µL deionized water was added and purified on
HPLC. The eluent from the HPLC corresponding to radioactive peak was collected. Product
identity was confirmed by co-injecting non-radioactive FIAC with the radioactive fraction onto
HPLC.
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CHAPTER 3: IN VITRO EVALUATION OF IODINE LABELED
NUCLEOSIDE ANALOGS
3.1

Introduction

After confirming the identity and purity of isolated radio-iodinated gem analogs, it is
essential to assess their biological activity in vitro before any in vivo PET imaging studies are
performed. To assess the utility of [124I]FIRC, [124I]Igem and [124I]FIAC as surrogate markers for
gemcitabine (gem), their uptake into cells and phosphorylation inside the cells are absolute
requirements. In vitro assays are effective initial tools that can be used to screen for molecules
with most promising biological activity. This also reduces the utilization of valuable resources that
are needed for in vivo studies - experimental animals and iodine-124, the expensive PET active
isotope needed for in vivo PET imaging. Thus, in vitro experiments using cancer cells and purified
enzymes were performed and results are presented in this chapter.
We systematically explore the steps involved in the metabolism of the non-PET active
radiolabeled gem analogs - [131I]FIRC, [131I]Igem and [131I]FIAC in pancreatic cancer cell lines.
The steps taken to evaluate the tracers in vitro closely follow the metabolism of gem as described
in Fig 1.3, namely transportation across the cell membrane, followed by phosphorylation and
incorporation into DNA.
Firstly, their transport across the cell membrane and accumulation in the cells by the end
of 2 hours will be explored. As seen in Fig 1.3, cell membrane is the first major barrier for
synthesized radioactive analogs [131I]FIRC, [131I]Igem and [131I]FIAC to mimic gem’s mechanism
of action. Despite having close structural similarity to gem, introduction of iodine on gem and its
analogs inadvertently changes the electronic and chemical properties of the analogs. While in silico
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modelling was performed to evaluate the affinity of the gem analogs to deoxycytidine kinase
(dCK), similar in silico modelling for transport across the cell membrane was beyond our scope.
Various kinds of cell uptake assays which provide different information will be performed.
Once it is confirmed that synthesized product/s are the substrates for dCK, their uptake in
two most widely used pancreatic cancer cell lines, AsPC-1 and MIA PaCa-2 will be explored.
Following the uptake of radiotracers in the cells, the nuclear and the cytosolic fractions will be
isolated to determine the fate of the radiotracer that show cell uptake. Finally, phosphorylation
efficiency of the iodinated analogs candidate/s that showed successful accumulation in the cells
will be evaluated utilizing purified deoxycytidine kinase (dCK). While the cell uptake assays
ensure that the gem analogs ability to cross the cell membrane and nuclear membrane, it is
important to understand the kinetics of phosphorylation with gem as a reference. To accomplish
the same, purified dCK will be incubated with the radioiodinated analogs of gem and the rate of
phosphorylation will be studied. By the end of this chapter, we will evaluate the suitability of the
radioiodinated analogs for in vivo studies.
3.2

Results and discussion
3.2.1

Comparison of cell uptake of [131I]FIRC, [131I]IGem and [131I]FIAC in
a pancreatic cancer cell line, AsPC-1

Radio-iodinated products, [131I]FIRC, [131I]IGem and [131I]FIAC were synthesized as
described in Chapter 2, pure fractions were collected from HPLC, their identity confirmed by coelution with their respective non-radioactive compounds. The radioactive analogs were diluted
with phosphate buffered saline (PBS) and used for further in vitro experiments. In vitro kinetic
uptake assay was performed on representative pancreatic cancer cells line, AsPC-1, by incubating
one million cells with radiolabeled drug (0.5-1 µCi (18.5-37 kBq)) for 2h. The cells were harvested
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onto a silica impregnated filter paper on a Brandel harvester. The filters were counted on a gamma
counter. Radioactivity in the collected cells was measured as an indication of uptake of radioactive
substrates.
After repeated attempts, while there was no uptake of [131I]FIRC and [131I]IGem by ASPC1 cells, [131I]FIAC showed a considerable uptake (Figure 3.1.). Similar uptake of [131I]FIAC and
lack of [131I]FIRC and [131I]IGem uptake was reflected in other cancer cells lines (Jukat, Raji, U87
and MIAPaCa-2) as well (Figure A.3.1). The activity in the cells from each well was measured
(in counts per minutes, CPM) gamma counter after 2 h incubation and the results are expressed as
the percentage of total activity added to the well (% total CPM).
As phosphorylation by dCK is the rate limiting step for the retention of the radioactive
analog of gem in cell, the uptake of the substrate by cell and affinity of substrate to dCK (from in
silico studies) were expected to be correlated. We predicted the iodinated gem analogs with higher
affinity (lower docking scores) to be taken up by the cells in higher amounts and vice versa. Thus,
in vitro uptake of the radioactive analogs was expected to follow the trend of affinity and the order
of uptake to be [131I]FIAC > [131I]FIRC > [131I]IGem. While [131I]FIAC’s in vitro uptake could be
explained by FIAC’s good affinity for dCK in silico, [131I]FIRC did not show any uptake in vitro
despite FIRC showing good affinity for dCK (almost a comparable docking score to gem, dC and
FIAC). While the lack of uptake of [131I]IGem by cells could be explained by poor docking score
for IGem in dCK’s active site, the FIRC uptake results are confounding. Nevertheless, the role of
transporters cannot be diminished as a reason for such results.
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Figure 3.1. Uptake of various radiolabeled gem analogs at the end of 2h incubation with AsPC-1
cells.

3.2.2

Comparison of [131I] FIAC uptake in a pancreatic cancer cell lines
AsPC-1 and MIAPaCa-2

Once it was confirmed that FIAC could be phosphorylated by dCK, we set out to test its
differential uptake in two pancreatic cancer cell lines - AsPC-1 and MIA PaCa-2. AsPC-1 and
MIA PaCa-2 cells are one of the most widely used cells for conducting experiments involving
pancreatic cancer cell lines.
Time dependent cell uptake assays were performed using [131I]FIAC, which was the only
substrate that showed uptake in AsPC-1 cells and was phosphorylated by dCK. Cellular uptake
assays showed that [131I]FIAC was taken up preferentially (4X) by AsPC-1 in comparison to
MIA PaCa-2 cell lines (Figure 3.3.).
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Various cell lines – both pancreatic and non-pancreatic were screened to study the
differential uptake of the synthesized radioactive analogs. Of the cell lines evaluated, AsPC-1 and
MIA PaCa-2 showed differential uptake of [131I]FIAC in vitro. AsPC-1 are derived from metastatic
site (ascites) and MIA PaCa-2 are from pancreas with epithelial morphology.

Figure 3.2. In vitro uptake of [131I]FIAC in human pancreatic cell line AsPC-1 and MIAPaca-2
showing time dependent uptake of [131I]FIAC in the cell line.

3.2.3

Competitive inhibition with gem in pancreatic cancer cell lines

The competitive inhibition uptake assays were performed by incubating two sets of cells
in triplicate with [131I]FIAC, one in presence and the other in absence of a huge molar excess of
gem (1 mM). Such assays have been used to identify the targets for newly synthesized compounds
including gem.1 When a radioactive molecule is incubated with excess of a non-radioactive
molecule both targeting the same enzyme, the uptake of radioactive molecule is diminished. As
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such, if [131I]FIAC and gem are both substrates for dCK, the uptake of [ 131I]FIAC could be
diminished by incubating [131I]FIAC with excess of gem.
In presence of high molar concentration of gem (~0.1M), the uptake of [131I]FIAC could
be inhibited in both AsPC-1 and MIA PaCa-2 cells. There was an average decrease to 35% of
total CPM in [131I]FIAC uptake in AsPC-1 cells while [131I]FIAC uptake decreased to 55% in
MIA PaCa-2 (Figure 3.4.). While the decrease in [131I]FIAC uptake suggests the target of
[131I]FIAC to be same as gem, the low inhibition values reflect the lower affinity to the same
enzyme.

Figure 3.3. Uptake of [131I]FIAC could be inhibited by excess of gem (0.1M solution in media)
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3.2.4

Intra-cellular localization of FIAC in AsPC-1 and MIA PaCa-2 cells

From previous experiments in this chapter, it was confirmed that [131I]FIAC was
taken up by the pancreatic cancer cells. Intracellular localization assays were performed to
determine the amount of [131I]FIAC being localized in the nucleus, which gives an insight into
DNA incorporation. After the incubation of cells with [131I]FIAC for 2 hours, cells were washed
and the cellular components (cytoplasm and nucleus) were collected. The radioactivity in each
compartment was measured to quantify the amount of [131I]FIAC in each compartment.
Majority of [131I]FIAC accumulated in nucleus for both AsPC-1 and MIA PaCa-2 cells
(Figure 3.5.) While almost 95-99% of total counts were localized in ASPC-1’s nucleus, the
[131I]FIAC in MIA PaCa-2’s nucleus was far less (around 70%).

Figure 3.4. Distribution of [131I]FIAC in AsPC-1 and MIA PaCa-2 cells
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3.2.5

In vitro phosphorylation assay

In vitro phosphorylation studies were conducted to study the efficacy of substrate
phosphorylation by dCK and the assay was performed as previously described.2, 3 Efficacy of
phosphorylation of [131I]IGem and [131I]FIAC by recombinant dCK enzyme was studied in
presence of ATP (phosphate source) and MgCl2 (Scheme 3.1). The percentage of phosphorylated
product is assessed by radio thin layer chromatography using polyethylimmine (PEI) charged
cellulose as the stationary phase and deionized water as mobile phase. The pH of the reaction
mixture reflected the human physiological pH of 7.2, at which the phosphorylated gem and its
analogs have a negative charge. When gem and gem analogs undergo phosphorylation catalyzed
by dCK in presence of ATP, the phosphorylated products tend to stay at the baseline owing to
strong interaction with positively charged PEI and the neutral non-phosphorylated precursors
move with the solvent front. [3H]-Gem was used as a standard for comparison (control).
While [3H]-Gem (control) was completely phosphorylated within 5 min, it was observed
that only 44% of [131I]FIAC was phosphorylated after 30 min of incubation with dCK in presence
of ATP. No further increase in the phosphorylation was observed with increased time of
incubations.
[131I]FIRC was not analyzed as substrate for phosphorylation by dCK because of its
inability to be taken up by cells. While [131I]IGem did not show any uptake in cells akin to
[131I]FIRC, El-Kawy and his group had previously reported that [125I]IGem was taken up by the
cells both in vitro and in vivo.4 Thus, phosphorylation assays were performed using [131I]IGem.
In our experimental conditions, [131I]IGem did not show any phosphorylation by dCK in
vitro. Lack of cellular uptake of [131I]IGem could be because of its inability to be phosphorylated
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by dCK. dCK phosphorylation assay revealed the efficiency of phosphorylation of GEM to be
much higher than [131I]FIAC (Figure 3.2.). Despite these results, [131I]FIAC showed only a slight
increase in cells transfected to express higher amounts of dCK in vitro (Figure A.3.1).

Scheme 3.1. Phosphorylation of 3H-Gem

Figure 3.5. iTLC of in vitro phosphorylation assay showing of a) 3H-Gem eluting with solvent
front b) phosphorylated product of 3H-Gem after 5 min of incubation with dCK c) phosphorylated
product of [131I]FIAC after 5 min of incubation with purified dCK and d) phosphorylated product
of [131I]IGem after 60 min of incubation with purified dCK.
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3.3

Conclusions
Among the three iodine-131 labeled gem analogs synthesized, [131I]FIAC was the only

gem analog that was definitively taken up by pancreatic cancer cells. Despite several attempts in
various cell lines, [131I]FIRC and [131I]IGem were not taken up by the cells. Given differential
response to gem, two pancreatic cancer cell-lines AsPC-1 and MIA PaCa-2 were chosen to
evaluate the potential of [131I]FIAC as marker for sensitivity to gem. [131I]FIAC accumulated in
higher amounts in the nucleus of AsPC-1 than the MIA PaCa-2. The reason for such confounding
results is not clear and will be explored in further chapters.
3.4

Experimental Section
[131I]FIRC, [131I]IGem and [131I]FIAC were synthesized as described in Section 2.5.
3.4.1

General methods and materials:

MTT assay kit was purchased from Roche, IN, USA (Product number 1146500700.)
Purified dCK was purchased from Abcam (cat: ab99520). Carrier-free [131I]NaI in 0.1N NaOH
was obtained from Nuclear Diagnostic Products (Rockaway, NJ, USA).
Phosphorylation efficiencies were determined by radio-instant thin-layer chromatography
using polyethylimmine-cellulose TLC plates (Sigma-Aldrich® Cat: Z122882).
3.4.2

Cell Lines

Pancreatic cancer cell lines AsPC-1 (adenocarcinoma, derived from metastatic site
(ascites)) and MIA PaCa-2 (epithelial carcinoma), were obtained from American Type Culture
Collection (ATCC, Manassas, VA) and grown in culture flasks (Cell Star 660 160; 550mL; 175
cm2). Cells were cultured in media obtained from media preparation core at MSKCC. AsPC-1 was
cultured in RPMI-1640 medium supplemented with fetal calf serum (FCS) to a final concentration
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of 10%. MIA PaCa-2 were grown in NEAA supplemented DME-HG:F12 (1:1) media
supplemented with 10% FCS, 2mM Glutamine, non-essential amino acid (NEAA), penicillin and
streptomycin. RIPA lysis buffer was purchased from Thermo-Fisher (Cat # 89900). Disposable
Cell culture tubes were purchased from Kimble (cat # 51012-100). Matrigel was purchased from
(Becton Dickinson procured via Thermo Fisher Scientific). Cell lines were authenticated by
Genetica Cell line testing (NC, USA) after the completion of experiment to verify that cells did
not undergo changes at molecular level during the passages.
3.4.3

In vitro assays of [131I]FIRC, [131I]IGem and [131I]FIAC in a
pancreatic cancer cell line, AsPC-1

3.4.3.1

In vitro time dependent uptake by PaCa cell line (AsPC-1)

Cells were grown to 70% confluency and a single cell suspension of live cells was made
using trypsin. 1 × 106 cells (2 × 106 cells/mL media) in quadruplicates were suspended in Kimble
polystyrene tubes. The cells were incubated with 0.5-1 µCi (18.5-37 kBq) of activity for
radiolabeled compounds [131I]FIAC (in 500 µL phosphate buffered saline) for 2 h. Cells were then
collected on silica filter paper using Brandel Harvester and radioactivity was counted on
WIZARD™. Counts were normalized to weight protein of 1 million cells. Final results are
expressed as (CPMcells/CPMmedia *100)/ µg protein in cells.
3.4.3.2

In vitro phosphorylation assay

[131I]FIAC (~1 µCi (37 kBq)) or [3H]-Gem was incubated with purified dCK (2 µL from
stock solution) in buffered (PBS - 25 µL) solution containing ATP (10 µL of 50 mM in 25 mM
MgCl2.6H20). The pH of the resulting solution was adjusted to 7.2 using HEPES buffer (~3 µL,
pH 8.5) and incubated at 37 ºC. ~ 0.1 µCi (3.7 kBq) aliquots were sampled at various time points
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starting at 0 min to 60 min, spotted on PEI cellulose TLC sheets and eluted with water as mobile
phase. The separation for the phosphorylated product and non-phosphorylated precursor was
analyzed using radioTLC scanner.
PEI TLC plates have a net positive charge. When negatively charged phosphorylated
nucleotide analogs are spotted on TLC and eluted using water, non-phosphorylated nucleoside
analogs move along with the solvent front and the negatively charged phosphorylated analog is
retained at the baseline. Radioactivity at the baseline and solvent front was measured and expressed
as percentage phosphorylated.
3.4.3.3

[131I]FIAC uptake in a pancreatic cancer cell lines AsPC-1 and
MIAPaCa-2 in vitro

Pancreatic cancer cell line AsPC-1, derived from metastatic site (ascites), was obtained
from American Type Culture Collection (Manassas, VA) and cultured in RPMI-1640 medium
supplemented with fetal calf serum (FCS) to a final concentration of 10% obtained from media
preparation core at MSKCC. AsPC-1 cells (5 × 105 in 2 mL media) were seeded in a six well plate
6-12 h prior to the beginning of the assay. Three wells were used for every time point to obtain
triplicate values. Cells were treated with [131I]FIRC, [131I]IGem or[131I]FIAC (1 µCi in 10 µL PBS)
for time ranging from 5 min to 180 min. After treating the cells for specified time period, the
supernatant was removed, cells were washed (3X) with ice cold PBS and lysed using RIPA lysis
buffer. The cell lysate was collected into cell culture tubes. Remaining cell lysate in each well was
extracted into the culture tubes by washing the wells with ice cold PBS (2X). Three wells were not
treated with radioactive analogs, lysed in similar manner and used for protein quantification using
Pierce™ BCA protein assay kit. The cell culture tubes containing the cell lysates were counted on
a Wizard automatic γ counter (Perkin Elmer, Boston, MA). The counts obtained as CPM were
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normalized to the protein content and expressed as CPM/ µg of total protein content in each well.
Cell lines were authenticated by Genetica Cell line testing (NC, USA) after the completion of
experiment to verify no-changes in the cells at molecular level.
3.4.3.4

Competitive inhibition of [131I] FIAC uptake in presence of
gemcitabine

Cells were grown to 70% confluency and a single cell suspension of live cells was made
using trypsin. 1 × 106 cells (2 × 106 cells/mL media) in quadruplicates were suspended in Kimble
polystyrene tubes. The cells were incubated with [131I]FIAC (0.5-1 µCi (18.5-37 kBq)in 500 µL
phosphate buffered saline) and gem (to achieve 1mM final concentration) for 2 h. Cells in triplicate
were incubated without gem which acted as control. Cells were then collected on silica filter paper
using Brandel Harvester and radioactivity was counted on WIZARD™. Counts were normalized
to CPM uptake in cells incubated without gem. Final results are expressed as the fraction
[131I]FIAC (as determined by CPM) in the cells incubated with gem.
3.4.3.5

Intra-cellular localization assay

Pancreatic cancer cell lines AsPC-1 and MIA PaCa-2 were incubated with [131I]FIAC (0.51 µCi (18.5-37 kBq)in 500 µL phosphate buffered saline) and cellular compartments were isolated
at the end of 2h as described in the nuclear extraction protocol using 10% NP40 cell lysis buffer
(Cat number FNN00021). Briefly, the cells were collected by centrifugation after detaching them
from the 6-well plates used for incubation with [131I]FIAC. The supernatant was discarded, and
the cell pellet was lysed by vortexing the cell pellet with lysis buffer (25 µL) for 10 sec. The
extracts were centrifuged at 3000 rpm for 10 min at 4 ºC. The supernatant was transferred and
saved as the cytoplasmic fraction while the rest of the pellet was saved as nuclear fraction.
Radioactivity was quantified with a WIZARDTM 3” 1480 gamma counter (Perkin Elmer, Waltham,
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MA, USA). Final results were expressed as percentage of total counts by adding the cytoplasmic
and nuclear counts to be 100% of the total counts (minor losses were neglected).
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CHAPTER 4: IN VIVO EVALUATION OF [124I]FIAC AS A MARKER OF
DCK EXPRESSION
4.1.

Introduction
The results from previous chapters indicated the need for longer-lived-isotope

labeled gemcitabine (gem) analogs to predict the potential of patients who would benefit from gem
treatment. Consequently, three different iodine-labeled nucleoside analogs were designed,
synthesized and tested in vitro for their ability to act as substrates for the deoxycytidine kinase
(dCK), the rate limiting enzyme responsible for activation of gem in vivo. Of the three nucleoside
analogs synthesized, the 2′-arabino isomer, [131I]FIAC was the only analog that showed uptake by
cancer cell lines in vitro, whereas the 2′-ribose analog [131I]FIRC and 2′,2′-difluro analog
[131I]IGem did not show any uptake. While in vitro phosphorylation assays determined that
[131I]FIAC was a substrate for dCK and that its uptake could be competitively inhibited by excess
of gem.
Following the results from previous chapters, this chapter will highlight the synthesis of
iodine-124 labeled FIAC followed by an investigation into the feasibility of using [124I]FIAC as
an imaging agent by studying properties in vivo in pancreatic cancers in preclinical mouse models.
[124I]FIAC will be first evaluated in athymic nude mice bearing AsPC-1 subcutaneous tumors to
replicate the in vitro uptake of the tracer in vivo, followed by mice bearing bilateral tumor models.
[124I]FIAC will be further evaluated in orthotopic tumor models of AsPC-1 cells and in PANC-1
subcutaneous tumor models.
After validating the radioactive tracers in vitro, studying in vivo uptake and the overall
pharmacokinetics of a tracer is the next crucial step. While in vitro studies offer an initial insight
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into tracer/drug properties, in some rare cases, in vitro properties do not necessarily predict the in
vivo pharmacology and response.1, 2
4.1.1

Brief history of FIAC

FIAC was discovered as result of pioneering efforts by Wright et. al. who
demonstrated that introducing fluorine in 2′-position on furanose sugar moiety sugar imparts
resistance to deaminase activity in vitro (87% less susceptible to deamination).3 Introduction of
fluorine in 2′-position of sugar imparts the extra stability to the entire nucleoside and offers
resistance against glycosidic bond cleavage, which was a huge problem for drugs such as ara-C
(3). Indeed, some of the most widely used chemotherapeutic nucleoside analogs are 2′-deoxy-2′fluoro nucleoside analogs such as gemcitabine (Gemzar®) and clofarabine (Clorar®). Currently,
nucleoside analogs are one of the most widely used classes of chemotherapeutics.
Discovered in the early 70’s, FIAC was found to be an excellent antiviral agent for
obviation of HSV-1 replication (>90 % reduction of HSV-1 in monolayer Vero cells at the
concentration of 0.01 µg/mL) and was cytotoxic to L5178Y (mouse lymphoma) and P815 (mouse
mastocytoma) cell lines at the concentrations of 48 and 14 µg/mL respectively.4 FIAC was found
to be cytotoxic to many human cell lines5 and metabolic fate of FIAC was studied in mice and
rats.6, 7 Preliminary results from in vivo studies indicated that FIAC at 1000 mg/kg daily for 5 days
had no significant effect in mouse leukemia P388, L1210, and P815.6, 8 Carbon-14 (C-14) labeled
FIAC incorporation was competitively inhibited by dCyd but not by dThy, to conclude that FIAC
behaves like dCyd. Also FIAC predominately inhibits dThd kinase and/or thymidine
monophosphate synthetase.7 Eventually FIAC was

found

to be a better antiviral than a

chemotherapeutic as it was found that FIAC metabolized into mono-, di-or tri-phosphates of FIAC
in virus infected cells and incorporated into viral DNA sequence to cause anti-viral effect in
68

concentration as low as 10 nM.9 FIAC was efficacious in treating human cyto-megalo virus in
human skin fibroblasts and in mice infected with HSV-TK intra-cerebrally.10, 11 Previous studies
have suggested that dCK is an important enzyme in the phosphorylation of FIAC and that FIAC
was incorporated in to DNA.12
Given the excellent antiviral activity of FIAC, there were two separate clinical trials
conducted for evaluating it as an antiviral against many viral types; Herpesvirus infection, Herpes
Zoster herpes simplex virus (HSV) types 1 and 2, varicella-zoster virus (VZV), and
cytomegalovirus (CMV) to name a few.13, 14 The trials were subsequently relinquished because of
acute toxicity to the patients and probably because of the emergence of an effective, relatively nontoxic nucleoside analog antiviral, acyclovir, at the same time.13, 15-17 However, as a byproduct of
the early clinical trials with FIAC, its in vivo pharmacokinetics are well known. Majority of the
studies were conducted using C-14 analog of FIAC.6 It was noted that at shorter infusions between
15-20 min, the blood half-life of the drug was 37 min and that the major metabolite was the
deaminated product 2′-deoxy-2′-fluoro-5-iodo-1-β-D-arabinofuranosyluracil, FIAU. Although
information on the half-life of triphosphates is not well documented, it was noted that FIAC
showed high uptake in organs such as spleen and SI.
While the potential of FIAC as a therapeutic agent failed, its potential as an imaging agent
was realized more recently. FIAC, having fluorine and iodine in the molecular structure, provides
us a unique possibility of synthesizing radiolabeled analogs using fluorine-18 (F-18) or Iodine124/131/123/125, without compromising the structural identity of the molecule. In efforts to
synthesize PET-active FIAC ([18F]FIAC) was synthesized and evaluated to image human simplex
virus thymidine kinase (HSV-TK) positive and negative cell lines.18, 19 Iodine-125 labeled agent
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1-(2-deoxy-2-fluoroβ-d-arabinofuranosyl)-5-iodocytosine ([125I]FIAC) was synthesized as well,
purified and studied as an anti-viral.20
4.2.

Results and discussion:
The potential of [124I]FIAC as an imaging agent was assessed in vivo in athymic

nude mice bearing subcutaneous (s.c.) AsPC-1 tumors. Once the mice acclimatized to the
vivarium, tumors were induced in mice either by inoculating the cancer cells subcutaneously or
into the pancreas. Tumors were allowed to reach a volume of 100 mm 3 before any imaging or
biodistribution studies were conducted. The radioactive analog was injected intravenously into the
tail vein and accumulation of radioactive iodine in thyroid was blocked using KI solution. Mice
(n=3) were anesthetized at the 4, 24, 48 and 72 h post injection and imaged under a preclinical
PET scanner. For the biodistribution studies, mice (n=5) were euthanized at 4, 24, 48 and 72 h post
injection (p.i.), organs harvested and the radioactivity in each organ was measured. The activity in
each organ was normalized to its measured weight and the uptake in each organ is reported as %
of injected dose per gram in that organ (%ID/g).
Based on modeling studies and our ability to label with longer lived isotope (Iodine124; t1/2 = 4.18 d), we concentrated our efforts on evaluating I-124 labeled analogs of gem, 5iodogemcitabine ([124I]IGem) and (2-Deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodocytosine
([124I]FIAC) as positron emission tomography (PET) biomarkers of gem response in vivo.
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4.2.1

Synthesis of 2′-Fluoro-2′-deoxy-1- β -D-arabinofuranosyl-5[124I]iodocytosine ([124I]FIAC)

[124I]FIAC was synthesized using the reaction conditions used for the synthesis of
[131I]FIAC (Scheme 4.1), Briefly, to a solution of 100 µg of FAC dissolved in deionized water
(100 µL) in an eppendorf tube, 4.0 mCi of [124I]NaI (75 µL in 0.05 N NaOH) and chloramine-T
(4µg, 2mg/mL solution in glacial acetic acid) were added and heated on a heating mantle at 95 °C
for 20 min. The reaction mixture was cooled to room temperature and 100 µL deionized water was
added and purified on HPLC. The eluent from the HPLC corresponding to radioactive peak was
collected. Product identity was confirmed by co-injecting non-radioactive FIAC with the
radioactive fraction onto HPLC.
[124I]FIAC was isolated in 17% yields on HPLC.

Scheme 4. 1. Synthesis of 2′-Fluoro-2′-deoxy-1- β -D-arabinofuranosyl-5-[124I]iodocytosine
([124I]FIAC)
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4.2.2
4.2.2.1

In vivo evaluation of [124I]FIAC
PET imaging of [124I]FIAC in mice bearing single
subcutaneous tumors: AsPC-1

Preliminary results showed that the tumors could not be delineated from the background at
4 h post injection of [124I]FIAC (Figure 4. 1.). [124I]FIAC showed uptake in tumor, stomach and
g.i. tract and accumulation in bladder at 24 h. The images clearly show the preferential retention
of [124I]FIAC in tumor at 48 h and 72 h while clearing from non-target organs. Volume of interest
(VOI) analysis on the 2D slices of images using the maximum pixel intensities, indicate uptake to
be around 0.1% ID/g(PET) which almost remains constant all through 72h. Despite the mice being
injected with 0.01 % solution of KI 1h prior to the injection of [124I]FIAC, the blocking effect on
thyroid seems to fade away by 24 h as evidenced clearly in the maximum intensity projection
(MIPS). MIPs are generated by compressing the 2D slices and projecting them as a single image.
Uptake in the thyroids and gastro-intestinal track suggests in vivo deiodination of
[124I]FIAC and uptake by sodium-iodide (Na-I) symporters. The accumulation of radioactivity in
bladder by the end of 24 h suggests the elimination of [124I]FIAC by the renal system. It is
interesting to note that there is no accumulation of [124I]FIAC in liver and heart, suggesting no
hepato-biliary system and clearance of [124I]FIAC from the blood pool respectively. Preferential
retention of [124I]FIAC in tumors and elimination from non-target organs results in high contrast
images as evidenced at 72h and strongly suggests a selective uptake in tumors.
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Figure 4. 1. In vivo distribution of [124I]FIAC in athymic nude mice bearing subcutaneous AsPC1 tumors on right forelimb showing transaxial, coronal slices (top) and maximum intensity
projection (MIP, dorso-ventral projection) of a representative mouse. AsPC-1 tumor is circled with
dotted line on the right front limb.

73

4.2.2.2

Biodistribution of [124I]FIAC in mice bearing subcutaneous
tumors: AsPC-1

For ex vivo biodistribution, mice injected with [131I]FIAC or [124I]FIAC were sacrificed at
4, 24, 48 and 72 h post injection and %ID/g values. Similar to the PET images, tumors show
preferential uptake and retention of radiolabeled FIAC, while the radioactivity is cleared from the
non-target organs such as g.i. track. Ex vivo biodistribution indicate the tumor uptake of ~ 0.2
%ID/g (Figure 4. 2. and Table 4.1.). While the trend of retention of radiolabeled analogs in
tumors over time reflects the imaging studies and perfectly corroborated, similar corroboration is
not seen in %ID/g values. Even though the overall uptake values are low (~0.2 %ID/g), the tumorto-muscle ratio at 72 h is almost 50 (49.6, Table 4.2.). High tumor or organ ratios were also
observed overall. While tumor to liver ratio was 25.15, tumor to stomach, tumor to small intestine
and tumor to large intestine ratios were 9.95, 2.93 and 8.06 respectively. Organs of lymphatic
system such as spleen and lymph nodes had the tumor to organ ratios of 6.35 and 10.94
respectively.
While the PET images provide a snapshot of the in vivo radiopharmacologic profile of
[124I]FIAC in the preclinical mouse model, an ex-vivo terminal biodistribution allows for direct
quantification of radiotracer uptake in each organ. As seen in the PET images, the tumors showed
preferential uptake and retention of radiolabeled FIAC while the vast majority of the radioactivity
was cleared through the non-target organs such as the g.i. tract. Unlike %ID/g in tumors estimated
to be 0.1 by ROI analysis on 2D images, the ex-vivo biodistribution showed tumor accumulation
of ~ 0.2 %ID/g.
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Figure 4.2. Biodistribution of [131/124I]FIAC in AsPC-1 subcutaneous tumor bearing athymic nude
mice at 4, 24, 48 and 72 post i.v.injection.
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4h

24h

48h

72h

%ID/g ± StDev

%ID/g ± StDev

%ID/g ± StDev

%ID/g ± StDev

Blood

0.008 ± 0.004

0.026 ± 0.014

0.005 ± 0.001

0.006 ± 0.003

AsPC-1 Tumor

0.224 ± 0.108

0.229 ± 0.062

0.210 ± 0.071

0.188 ± 0.038

Heart

0.008 ± 0.004

0.010 ± 0.002

0.006 ± 0.002

0.007 ± 0.003

Lungs

0.023 ± 0.021

0.016 ± 0.006

0.007 ± 0.001

0.010 ± 0.004

Liver

0.011 ± 0.006

0.017 ± 0.005

0.008 ± 0.001

0.007 ± 0.002

Spleen

0.075 ± 0.060

0.058 ± 0.015

0.022 ± 0.008

0.030 ± 0.017

Stomach

0.021 ± 0.013

0.062 ± 0.037

0.021 ± 0.009

0.019 ± 0.010

S. Intestine

0.185 ± 0.162

0.221 ± 0.112

0.180 ± 0.010

0.064 ± 0.024

L. Intestine

0.039 ± 0.020

0.082 ± 0.037

0.033 ± 0.013

0.023 ± 0.009

Kidneys

0.013 ± 0.003

0.023 ± 0.005

0.011 ± 0.004

0.009 ± 0.002

Muscle

0.006 ± 0.002

0.011 ± 0.003

0.005 ± 0.002

0.004 ± 0.002

Bone

0.053 ± 0.031

0.078 ± 0.021

0.048 ± 0.019

0.020 ± 0.009

Tail

0.020 ± 0.014

0.106 ± 0.034

0.041 ± 0.042

0.029 ± 0.025

Thyroid

4.319 ± 4.621

1.318 ± 0.477

1.211 ± 0.105

1.135 ± 0.375

Lymph nodes

0.022 ± 0.008

0.028 ± 0.008

0.013 ± 0.003

0.017 ± 0.008

Table 4.1. Full biodistribution data including all tissues collected. All values expressed as
%ID/g.
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AsPC-1 Tumor/organ
4h

24h

48h

72h

Blood

27.99

8.65

38.33

30.64

AsPC-1 Tumor

1.00

1.00

1.00

1.00

Heart

27.46

22.22

33.73

28.37

Lungs

9.80

14.78

28.87

18.47

Liver

20.00

13.57

26.00

25.15

Spleen

2.99

3.95

9.40

6.35

Stomach

10.48

3.71

9.79

9.95

S. Intestine

1.21

1.04

1.17

2.93

L. Intestine

5.75

2.80

6.30

8.06

Kidneys

17.51

10.02

19.46

20.63

Muscle

39.31

20.50

45.00

49.60

Bone

4.25

4.95

4.38

9.62

Tail

11.21

2.16

5.11

6.57

Thyroid

0.05

0.17

0.17

0.17

Lymph nodes

10.24

8.09

15.78

10.94

Table 4.2. Tumor to organ ratios normalized to tumor.
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4.2.2.3

PET imaging of [124I]FIAC in mice bearing bilateral
subcutaneous tumors: AsPC-1 and MIAPaCa-2

Confirming the uptake of [131I]FIAC in vivo in mice bearing AsPC-1 tumors,
potential of [124I]FIAC to differentiate tumors of different sensitivity to gem was evaluated in
murine models bearing bilateral tumors AsPC-1 and MIA PaCa-2 to confirm the in vitro tracer
uptake. In vivo experiments were performed in athymic nude mice bearing subcutaneous AsPC-1
and MIA PaCa-2 tumors on fore limbs.
Similar to the previous section, AsPC-1 tumors were clearly visualized (Figure 4.
3.). While AsPC-1 tumors were clearly visualized, MIA PaCa-2 showed uptake in similar levels
as background. Similar distribution in gastro-intestinal tract was observed. While the %ID/gPET in
MIA PaCa-2 was below detectable level, the %ID/gPET in AsPC-1 was 1.91 ± 0.21, 0.35 ± 0.03,
0.1 ± 0.01 and 0.05 ± 0.001 at 4, 24, 48 and 72 h respectively. Clearly, %ID/gPET values calculated
in mice bearing bilateral tumors were not same as the %ID/gPET calculated from PET images in
mice bearing AsPC-1 tumors alone.

78

Figure 4.3. Representative transaxial, coronal slices (top panel) and maximum intensity projection
(MIP, dorso-ventral projection, lower panel) of a representative athymic nude mouse bearing
subcutaneous tumors (dorsal view) showing distribution of [124I]FIAC uptake in mice at 4h, 24h,
48h and 72h post i.v. injections in mice. AsPC-1 is circled with blue-dotted line on the left shoulder
while the MIA PaCa-2 is circled with white dotted line on the right shoulder.
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4.2.2.4

Biodistribution of [124I]FIAC in mice bearing bilateral
subcutaneous tumors: AsPC-1 and MIAPaCa-2

Ex vivo biodistribution studies revealed the uptake of [124I]FIAC in AsPC1 and MIA PaCa-2 xenografts was 1.19 + 0.23 and 0.32 + 0.08 %ID/g at 4 h, 0.47 + 0.14 and 0.05
+ 0.02 %ID/g at 24 h, 0.48 + 0.19 and 0.06 + 0.01 %ID/g at 48 h and 0.21 + 0.05 and 0.02 + 0.002
%ID/g at 72 h respectively (Figure 4. 4.). The trend in the biodistribution of [124I]FIAC in the
organs showed similar trend of

[124I]FIAC uptake in mice bearing AsPC-1 tumors alone;

nevertheless values were different (Table 4.3.). Tumor to background muscle ratios was also high
(Table 4.4.).

Figure 4.4. Biodistribution of [131/124I]FIAC in AsPC-1 and MIAPaCa-2 subcutaneous tumor
bearing athymic nude mice at 4, 24, 48 and 72 post i.v. injection.
80

4h

24h

48h

72h

Blood

0.478 ± 0.187

0.018 ± 0.004

0.031 ± 0.013

0.009 ± 0.004

AsPC-1

1.193 ± 0.202

0.472 ± 0.126

0.484 ± 0.166

0.208 ± 0.047

Mia PaCa-2

0.321 ± 0.076

0.050 ± 0.013

0.057 ± 0.01

0.019 ± 0.002

Heart

0.241 ± 0.071

0.012 ± 0.007

0.016 ± 0.006

0.004 ± 0.001

Lungs

0.244 ± 0.085

0.029 ± 0.016

0.029 ± 0.012

0.038 ± 0.023

Liver

0.205 ± 0.084

0.018 ± 0.005

0.0206 ± 0.005

0.008 ± 0.001

Spleen

1.031 ± 0.338

0.220 ± 0.132

0.080 ± 0.021

0.057 ± 0.021

Stomach

2.620 ± 0.737

0.124 ± 0.018

0.273 ± 0.146

0.039 ± 0.011

Sm. intestine

0.489 ± 0.230

0.667 ± 0.373

0.646 ± 0.133

0.191 ± 0.137

Lg. intestine

2.37 ± 0.670

0.137 ± 0.047

0.151 ± 0.045

0.038 ± 0.012

Kidneys

0.387 ± 0.171

0.022 ± 0.005

0.028 ± 0.009

0.008 ± 0.002

Muscle

0.160 ± 0.039

0.017 ± 0.005

0.037 ± 0.050

0.002 ± 0.001

Bone

0.463 ± 0.191

0.279 ± 0.165

0.131 ± 0.059

0.072 ± 0.041

Tail

0.489 ± 0.227

0.180 ± 0.262

0.050 ± 0.002

0.029 ± 0.010

Lymph nodes

0.266 ± 0.089

0.032 ± 0.016

0.048 ± 0.017

0.014 ± 0.008

Table 4.3. Comparison of [131/124I]FIAC in AsPC-1 and MIAPaCa-2 tumors.
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AsPC-1 Tumor/organ
4h

24h

48h

72h

Blood

2.49

25.79

15.65

24.27

AsPC-1

1.00

1.00

1.00

1.00

MIA PaCa-2

3.72

9.39

8.53

10.66

Heart

4.96

39.98

29.81

51.68

Lungs

4.89

16.56

16.50

5.43

Liver

5.81

26.72

23.44

26.51

Spleen

1.16

2.15

6.07

3.67

Stomach

0.46

3.81

1.77

5.37

S. Intestine

2.44

0.71

0.75

1.09

L. Intestine

0.50

3.43

3.21

5.50

Kidneys

3.08

21.16

17.26

26.16

Muscle

7.43

27.67

13.04

91.12

Bone

2.57

1.69

3.69

2.88

Tail

2.44

2.63

9.60

7.15

Lymph nodes

4.48

14.56

9.99

14.73

Table 4.4. Tumor to organ ratios normalized to tumor.
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Despite [131I]FIAC and [124I]FIAC being exactly the same compound, the uptake values
were quite different between independent experiments while retaining the same trend in uptake
between the organs. In cohorts of bilateral tumor bearing mice injected with [131I]FIAC (sacrificed
4, 24 and 48h post injection, Table 4.3), the %ID/g were considerably higher than the mice bearing
AsPC-1 alone injected with [124I]FIAC (Table 4.1). While the %ID/g was 6X higher for bilateral
tumor bearing mice at 4 h, it was almost double at 24h and 48h. However, in both the experiments
[124I]FIAC was injected into mice bearing tumors sacrificed 72h post injection, these cohorts show
similar uptake.
Such difference in biodistribution between the isotopes, iodine-124 and iodine-131 is not
normal unless a different compound is injected or there is an experimental error. Prior to in vivo
experiments, the identity of the radioactive compound was always verified by coeluting the
radiotracer with cold analog. To determine the cause, all data was re-evaluated and no errors were
found. The experiment was repeated with [131I]FIAC in bilateral tumor bearing mice. While the
uptake in AsPC-1 tumor was higher than MIA PaCa-2 in all the mice, the difference was
diminished because of huge variability in data (Table A.4.1). Similar to previous experimental
data (Table 4.3), There was a significant reduction in the tracer uptake at 72h PI in all organs
except thyroid, spleen, bone and tumor AsPC-1. Unlike the previous experiment (Table 4.3), most
of the activity was recovered from the stomach and not thyroid. All the above results clearly
indicate an experimental error.
4.2.2.5

PET imaging of [124I] FIAC in mice bearing orthotopic AsPC-1
tumors

While subcutaneous tumors present a good approximation of human tumors in vivo,
orthotopic tumors that grow directly in the pancreas better mimic the tumor environment. Once
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the utility of [124I]FIAC as an imaging agent was established in subcutaneously xenografted AsPC1 tumor-bearing mice, its potential to image orthotopic tumors with this radiotracer was explored
by imaging surgically implanted AsPC-1 cells in mouse pancreas. All 5 mice that were implanted
with cells developed into tumors which could be clearly visualized using [124I]FIAC.
Five mice bearing orthotopic AsPC-1 tumors were injected with of [124I]FIAC (200 µCi or
7.4 MBq in 150 µL 0.9% sterile saline) intravenously, imaged under PET at 24, 48 and 72h. The
mice were sacrificed at the end of 72h, organs were harvested, weighed and the uptake of
[124I]FIAC was calculated and expressed as %ID/g. PET images indicated that [ 124I]FIAC
distribution in mice bearing orthotopic tumors closely resembles the distribution of radiotracer in
mice bearing subcutaneous tumors.
The tumor was clearly delineated in the PET images and a high contrast was obtained
between the tumor and its background (Figure 4. 5.). Orthotopically implaneted pancreatic tumors
were clearly imaged in mice despite being surrounded by organs such as the liver, stomach, small
intestine and large intestine.
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Figure 4.5. PET imaging profile of [124I]FIAC in an orthotopic model of pancreatic cancer. In
vivo distribution of [124I]FIAC in athymic nude mice bearing orthotopic AsPC-1 tumors showing
transaxial and coronal slices of a representative mouse.

4.2.2.6

Biodistribution of [124I]FIAC in mice bearing orthotopic
tumors: AsPC-1

Five mice bearing orthotopic AsPC-1 tumors were sacrificed at the end of 72h and organs
were harvested and the uptake of [124I]FIAC was calculated and expressed as %ID/g (Figure 4.6.,
Table 4.5.). The profile of [124I]FIAC uptake in mice bearing orthotopic tumors closely resembled
that in mice bearing subcutaneous tumors. Similar profile of uptake in tumors and the g.i. tract was
observed. Similar to the results for this radiotracer used in the subcutaneous xenograft model, the
uptake of [124I]FIAC in liver, spleen, lungs and stomach was low compared to its uptake in the
tumor.
Such an uptake profile in the organs surrounding the pancreas is advantageous in
developing new imaging agent for pancreatic tumors, which can potentially provide better contrast
than currently available PET agents used to image this malignancy.
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Figure 4.6. Biodistribution of [131/124I]FIAC in surgically implanted orthotopic AsPC-1 tumor
bearing athymic nude mice at 72 h post i.v. injection.
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%ID/g ± StDev Tumor to Organ Ratio
Blood

0.006 ± 0.002

50.38

AsPC-1 Orthotopic

0.301 ± 0.094

1.00

Heart

0.006 ± 0.001

51.98

Lungs

0.044 ± 0.018

6.78

Liver

0.009 ± 0.003

32.36

Spleen

0.079 ± 0.032

3.80

Stomach

0.022 ± 0.003

13.87

Sm. Intestine

0.174 ± 0.083

1.73

Large Intestine

0.040 ± 0.014

7.47

Kidney

0.013 ± 0.008

23.32

Muscle

0.003 ± 0.000

90.58

Bone

0.055 ± 0.016

5.48

Tail

0.041 ± 0.037

7.31

Lymph node

0.066 ± 0.040

4.54

Thyroid

5.555 ± 1.264

0.05

Table 4.5. Full biodistribution data and tumor to organ ratios of all tissues collected. All values
expressed as %ID/g.
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4.2.2.7

PET imaging and bio distribution of [124I]FIAC in mice
bearing single subcutaneous tumors: PANC-1

To test the feasibility of [124I]FIAC as an imaging agent, a small cohort (n=3) of mice were
implanted with PANC-1 tumors on right hind limb and imaged over same time points as mice
bearing AsPC-1 tumors. Both the imaging and the biodistribution results in mice bearing PANC1 tumors mimicked the uptake and distribution of [124I]FIAC in mice bearing AsPC-1 tumors. The
tumors showed an uptake of 0.3% ID/g with high tumor to background ratios (Figure 4.7.).
PANC-1 cells were chosen to evaluate the utility of Iodine-124 labeled FIAC in pancreatic
tumor models other than AsPC-1 and MIA PaCa-2. PANC-1 cells are of pancreatic ductal origin
with epithelial morphology, while AsPC-1 are derived from metastatic site (ascites) and MIA
PaCa-2 are from pancreas with epithelial morphology. Similar to previous experiments, [124I]FIAC
was injected through tail vein and the mice were imaged at 4h, 24h, 48h and 72h post injection.
The mice were sacrificed at the end of 72 hours, organs were harvested and the %ID/g was
calculated by normalizing the radioactivity in organs to their respective weights.
PET Imaging showed similar distribution in mice organs with most of the activity in gut
and preferential retention in tumors while clearing out from other organs. The tumors could be
clearly visualized at 72h post injection. Biodistribution results showed a similar trend of uptake in
various organs. Interestingly, despite being morphologically similar to MIA PaCa-2, the %ID/g
uptake in the tumor was very different (0.3% ID/g in PANC-1 compared to 0.02% ID/g in MIA
PaCa-2.). More experiments to evaluate the levels of different enzymes in cells of similar origin
might shed light on such differences in uptake.
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Figure 4.7. Biodistribution of [131/124I]FIAC in PANC-1 subcutaneous tumor bearing athymic
nude mice at 4, 24, 48 and 72 post i.v. injection.
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4.3.

Conclusions
In this chapter, we report the synthesis of I-124 labeled FIAC, [124I]FIAC and its utility to

preclinically image human pancreatic tumor xenografts. While [ 124I]FIAC appears to be a fairly
good PET imaging agent for both AsPC-1 and PANC-1 tumors, delivering high contrast images
at later time points, the anomaly in the uptake of [124I]FIAC in AsPC-1 and MIA PaCa-2 in vitro
was reflected in in vivo experiments as well.
In the preclinical models of pancreatic cancer using the AsPC-1 cell line, the radiolabeled
nucleoside analogs of FIAC ([124I]FIAC or [131I]FIAC) demonstrated time dependent uptake in
both subcutaneous as well as orthotopic tumors yielding preferential uptake and retention in tumor
while clearing from other organs. In sum, [124I]FIAC showed relatively high tumor uptake, longer
retention times and yielded high tumor-to-background ratio in preclinical models bearing AsPC-1
tumors.
Ex vivo terminal biodistribution of [124I]FIAC in various tissues was performed to directly
quantify uptake of the radiotracer. Similar to results obtained with the subcutaneous tumor model,
the uptake of [124I]FIAC in the liver, spleen, lungs and stomach was very low in comparison to the
tumor. Such uptake profile in the organs surrounding pancreas would be a favorable feature of a
new imaging agent for pancreatic cancer, by virtue of its ability to provide higher contrast images
than currently available PET agents used for the imaging of pancreatic cancer.
To test the feasibility of [124I]FIAC as an imaging agent in other kinds of pancreatic
tumors, a small cohort (n = 4) of mice were implanted with PANC-1 tumors on right hind limb
and were imaged at 4, 24, 48 and 72h time points, similar to mice bearing AsPC-1 tumors. Both
the imaging and the biodistribution results in mice bearing PANC-1 tumors mimicked the uptake
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and biodistribution profile of [124I]FIAC in mice bearing AsPC-1 tumors. The tumors showed an
uptake of 0.3% ID/g of this tracer with high tumor to background ratios being achieved in these
models.
The uptake values from biodistribution (%ID/g) did not show any correlation with uptake
values calculated from PET images using ASIPro (%ID/gPET). In mice bearing subcutaneous AsPC1 tumors, %ID/gPET remained 0.1 from 24 to 72h. In mice bearing bilateral tumors, while the
%ID/gPET in MIA PaCa-2 was below detectable level, the %ID/gPET in AsPC-1 was 1.91 ± 0.21,
0.35 ± 0.03, 0.1 ± 0.01 and 0.05 ± 0.001 at 4, 24, 48 and 72 h respectively. Clearly, %ID/gPET values
do not correspond to %ID/g calculated by biodistribution (Table 4.3). Despite repeated attempts
to quantify the data (within reasonable confidence), the uptake data remains inconclusive.
4.4

Experimental
4.4.1

General methods and materials

Carrier-free [131I]NaI in 0.1 N NaOH was obtained from Nuclear Diagnostic Products
(Rockaway, NJ, USA) and Carrier-free [124I]NaI in 0.1 N NaOH was obtained from the
Radioisotopes and Molecular Imaging Probes (RMIP) core facility at MSKCC.
HPLC purification and analysis were performed on a Shimadzu HPLC system equipped
with a binary high-pressure gradient solvent delivery module LC 10A and SPD-20A UV dual
wavelength detector connected to a bioscan flow-count radio-HPLC detector system for gamma
detection. Crude products were purified and analyzed for purity on reversed phase C18 column
using Phenomenex® Gemini 5 µm, 250 x 4.6 mm 110 Å [00G-4435-E0]. Purification and analysis
were carried out using an isocratic solvent system of 8% acetonitrile in 0.1% trifluoroacetic acid
at a flow rate of 1 mL/min. Radioactivity was quantified with a WIZARDTM 3” 1480 gamma
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counter (Perkin Elmer, Waltham, MA, USA) or a dose calibrator (Capintec® CRC-30BC, Ramsey,
USA).
Cell Lines
Cell lines were cultures and maintained as previously described in Chapter 3. Matrigel was
purchased from (Becton Dickinson procured via Thermo Fisher Scientific). Cell lines were
authenticated by Genetica Cell line testing (NC, USA) after the completion of experiment to verify
that cells did not undergo changes at molecular level during the experiments.
Xenograft models:
6-8 week old female athymic nude mice (Hsd:Athymic Nude-Forxn1nu) were obtained
from Envigo RMS, Inc. (Indianapolis, IN), and were allowed to acclimatize at least for 1 week.
All animal studies were reviewed and approved by MSKCC’s Institutional Animal Care and Use
Committee (protocols 86-02-020 and 08-07-013) and followed the National Institute of Health
guidelines for animal welfare.
In vivo Animal PET imaging and Biodistribution:
PET images were obtained with the mice under anesthesia in medical air (2 L/min, 2%
isoflurane, Baxter Healthcare, Deerfield, IL, USA) either on Focus 120 microPET (Concorde
Microsystems, Knoxville, TN) or Inveon PET-CT (Siemens, TX, USA). All images are either
analyzed by ASIPro VM (Concorde Microsystem) or INVEON research workspace (Siemens).
Using ASIPro, maximum pixel value was recorded for tumors. Post-reconstruction smoothing was
applied for visual representation of images in the figures. Mice and euthanized by CO2
asphyxiation at predetermined time points and organs were harvested. Activity in syringe prior to
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injection and after injection was used to determine the total activity administered referred to as
injected dose (ID). Activity in the collected organs was measured on WIZARDTM 3” 1480 gamma
counter (Perkin Elmer, Waltham, MA, USA). Count data were background and decay-corrected
to the time of injection and %ID/g for all the organs was calculated by weighing the organs. The
average and standard deviation of the %ID/g was determined using Graphpad Prism version 6.07
for Windows (Graphpad software, San Diego, CA, USA, www.graphpad.com). All animal studies
were reviewed and approved by MSKCC’s Institutional Animal Care and Use Committee
(protocols 86-02-020 and 08-07-013) and followed the National Institute of Health guidelines for
animal welfare.
4.4.2

Synthesis of 2′-fluoro-2′-deoxy-1-b-D-arabinofuranosyl-5-[124I]iodocytosine [124I]FIAC (35):

To a solution of 100 µg of FAC dissolved in deionized water (100 µL) in an eppendorf
tube, [124I]NaI (50-75 µL in 0.1 N NaOH) and chloramine-T (6µg, 2mg/mL solution in glacial
acetic acid) were added and heated on a heating mantle at 95 °C for 20 min. The reaction mixture
was cooled to room temperature and 100 µL deionized water was added and purified on HPLC.
The eluent from the HPLC corresponding to radioactive peak was collected. Product identity was
confirmed by co-injecting non-radioactive FIAC with the radioactive fraction onto HPLC (see
supplementary for HPLC).
4.4.3

Subcutaneous (s.c.) xenograft model:

6-8 week old female athymic nude mice were obtained from Charles River Laboratories
and were allowed to acclimatize at least for 1 week. AsPC-1 cells (5 × 106) were suspended in 1:1
mixture of Matrigel (Becton Dickinson) in cell culture medium (100 µL) and were injected
subcutaneously (s.c.) on right forelimb of mice. Tumors were allowed to grow for 2-3 weeks to
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reach a minimum size of 100 mm3 before any studies were performed. Similarly, PANC-1 cells (5
× 106) obtained from ATCC and grown in DMEM (+ 10% FCS) were injected on right hind limb
of nude female athymic mice. Tumors were allowed to grow for 2-3 weeks to reach a minimum
size of 100 mm3 before any studies were performed. Bilateral tumors were inoculated by injecting
5 × 106 cells suspended in 200 µL 1:1 v/v mixture of basement membrane (BD (Matrigel,
Collaborative Biomedical Products) and media on both forelimbs (AsPC-1 on the left and MIA
PaCa-2 on the right). Experiments were performed when the tumor size was between 100-200
mm3.
4.4.4

Orthotopic xenograft model:

For orthotopic pancreatic xenografts, female athymic nude were obtained from Charles
River Laboratories and were allowed to acclimatize at least for 1 week. The surgery was performed
as described by Houghton et al21. Briefly, mice were anaesthetized with 2% isoflurane gas in
medical air at a rate of 2 L/min and small animal surgery was performed on heated platform to
help mice maintain body temperature. Bupivacaine, a local anesthetic was injected intradermally
in the area surrounding the incision line. Skin was prepped for surgery, using alternating scrubs of
povidone-iodine and 70% ethanol. A longitudinal incision (0.5-1 cm) was marked in the skin and
the peritoneum, allowing for the spleen and pancreas to be exteriorized. AsPC-1 cells (5 × 105 in
1:1 mixture of Matrigel and cell culture medium (25 µL)) were slowly injected into the
parenchyma of the pancreas. The spleen and the pancreas were returned to the peritoneal cavity,
the peritoneal wall closed using 4-0 vicryl sutures and the skin was closed using wound clips.
Buprenorphine was administered before the recovery and dosage was repeated post-surgery as
needed every 4-6 h. The development and size of tumors was verified by ultrasonography (Vevo
2100 micro Ultrasound) and physical palpitation in 2-3 weeks.
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4.4.5

PET and PET/CT imaging

Female athymic nude mice (n = 3-5) bearing either s.c. tumors (100 mm3) or orthotopic
tumors (palpable and confirmed by ultrasound) were injected with [124I]FIAC (200 µCi or 7.4 MBq
in 150 µL 0.9% sterile saline) via tail. To minimize the uptake of free iodide by thyroid, mice were
injected with 0.01 %KI solution intraperitoneally (i.p.) 1 h before the active was administered. The
mice injected with [124I]FIAC were anaesthetized with 2% isoflurane gas in medical air at a rate
of 2 L/min and imaged either on microPET Focus scanner (Concorde Microsystems) or Inveon
PET/CT scanner (Siemens Healthcare Global) for 15 min at 4, 24, 48 and 72 h post injection. The
images were analyzed using ASIPro VM software or Inveon Research Workplace software and
optimized to show localization of PET signal. Using ASIPro, maximum pixel value was recorded
for tumors. Post-reconstruction smoothing was applied for visual representation of images in the
figures.
4.4.6

Biodistribution

Tumor bearing athymic nude mice were injected with [131I]FIAC or [124I]FIAC (25-50
µCi (0.93 - 1.85 MBq)) via tail vein Mice and euthanized by CO2 asphyxiation at predetermined
time points (24, 48 and 72 h) and organs were harvested. Activity in syringe prior to injection and
after injection was used to determine the total activity administered referred to as injected dose
(ID). Activity in the collected organs was measured on WIZARDTM 3” 1480 gamma counter
(Perkin Elmer, Waltham, MA, USA). Count data were background and decay-corrected to the time
of injection and %ID/g for all the organs was calculated by weighing the organs. The average and
standard deviation of the %ID/g was determined using Graphpad Prism version 6.07 for Windows
(Graphpad software, San Diego, CA, USA, www.graphpad.com)
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CHAPTER 5: COMPARISON OF IODINE-LABELED FIAC WITH [18F]FAC
AS A MARKER FOR DCK EXPRESSION
This chapter is an adaption of published work and is reproduced in part, from Gangangari KK,
Humm JL, Larson SM, Pillarsetty NVK. TMSOTf assisted synthesis of 2′-deoxy-2′-[18F]fluoro-βD-arabinofuranosylcytosine ([18F]FAC). PLoS ONE 2018 13 (5): e0196784.
Copyright: © 2018 Gangangari et al. This is an open access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original author and source are credited.
5.1

Introduction
In previous chapters, we have shown that while [124I]FIAC showed a good uptake in

pancreatic cancer cell line AsPC-1 in vitro and in vivo. However, it did not show correlation to the
sensitivity of pancreatic cancer cell lines AsPC-1 and MIA PaCa-2 to gem. To investigate further
the atypical uptake of [124I]FIAC in AsPC-1 and MIA PaCa-2, we compare [124I]FIAC uptake to
the uptake of a [18F]FAC, a well-established PET active substrate for dCK. We optimized the
synthesis of [18F]FAC for manual synthesis and shortened the overall steps in synthesis. We further
validate our uptake results by evaluating the levels of dCK (mRNA and protein in various cell
lines) encoding for it and comparing the [124I]FIAC to the uptake of tritium labeled gem [3H]-Gem.
5.1.1

Need to develop new methods for the synthesis of [18F]FAC

[18F]FAC (2′-deoxy-2′-[18F]fluoro-β-D-arabinofuranosylcytosine, 21) is a versatile probe
for imaging deoxycytidine kinase (dCK) expression levels in vivo. dCK is responsible for
phosphorylation of deoxycytidine (dC, 2) and other nucleoside analogs, plays a key role in immune
activation and has demonstrated to be one of the key enzymes in activating nucleoside-based drugs
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including gemcitabine. Previous synthesis of [18F]FAC (Scheme 5.1.) was based on the original
synthesis of cold fluorinated analog FAC by Wright and Fox’s well known nucleophilic
substitution method.1 This multistep synthesis has been adapted to synthesis of various flourine18 labeled nucleosides including 2′-deoxy-2′-fluoro-5-iodo-1-β-D-arabinofuranosylcytosine
([18F]FIAC)2 and other uridine derivatives.3 Briefly, [18F]FAC (21) was synthesized starting from
flourine-18 labeling of commercially available precursor 37 followed by activation of C-1 of sugar
with bromine using HBr in acetic acid (HOAc) to facilitate condensation with cytosine silyl
derivative (36). Excess of HBr is evaporated using toluene before adding 36 followed by
deprotection and HPLC purification of alpha and beta anomers.

Scheme 5.1. Classical synthesis of [18F]FAC employing HBr for activation and coupling to the
cytosine silylether developed by Radu’s group.
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Although this method yields an efficient synthetic route to [18F]FAC, it presents some
limitations. HBr/HOAc is corrosive; therefore, performing synthesis using commonly available
automated synthesizers needs corrosion resistant tubing and valves. Moreover, careful drying is
required as leaving excess of acetic acid may lead to sugar hydrolysis thus lowering the yields of
[18F]FAC. Overall, in our experience, this method provides moderate yields of [18F]FAC and has
been successfully automated by other groups using Elixys® radiosynthesizer with excellent yields
by other groups.4 In an effort to reduce the complexity of the synthesis, a one-step late stage
fluorination of [18F]FAC was developed by Meyer et. al.5 with comparable total synthesis time and
moderate yield of 4.3–5.5% (d.c). This method presents advantages of elimination of many
intermediate steps, but the precursor synthesis is challenging and is not commercially available.
Therefore, we explored methods to reduce the complexity of the synthesis of [18F]FAC.
We have previously published trimethylsilyltriflate (TMSOTf)-assisted methodology
based on Vorburggen’s trimethylsilyl triflate assisted coupling to synthesize fluorine-18 labeled
2′-deoxy-2′-fluoro-5-iodo-1-β-D-arabinofuranosyluracil (FIAU) and other 5-substituted uracil
derivatives to give alpha and beta anomers of 5-substituted uridine derivatives directly from the 1benzoyl sugar (38) instead of corresponding 1-bromo-derivative.6-8 Vorbruggen reported that Nglycosidic bond between sugars and the pyrimidine bases could be made using TMSOTf or strong
Lewis acid such as SnCl4 as a catalyst. This method using TMSOTf or strong Lewis acid such as
SnCl4 as a catalyst completely reduced the overall synthesis by 2 steps - bromination and
evaporation of excess HBr.
Herein, we report an alternative trimethylsilyl trifluoromethanesulfonate (TMSOTf)
assisted three step synthesis of [18F]FAC that eliminates the need for bromination and drying steps
with comparable reaction time and yields for total synthesis. The reduction in number of steps,
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purifications and reaction times makes this new method amenable to manual synthesis in one pot
with a potential to automate using conventionally available synthesizers (two pots as compared to
Elixys®’s multiple pots) without need for significant modifications.
5.2

Results and discussion
5.2.1

Synthesis of [18F]FAC and in vitro and in vivo comparison with
[131F]FIAC

5.2.1.1

Improved synthesis of [18F]FAC (2′ -deoxy-2′-[18F]-fluoro--D(arabinofuranosyl)cytosine) (1).

We developed a simple and concise method for the synthesis of [18F]FAC. [18F]FAC (anomer) was synthesized with average isolated decay corrected yield of 10.59 + 4.2 % (n = 6) with
radiochemical purity of >95% and total synthesis time of 158 + 19 min.
An alternative method for synthesis of [18F]FAC (1) was developed that reduces the
number of steps of conventional synthesis by 2 with comparable yields and synthesis times. Lewis
acid TMSOTf was utilized for direct coupling of un-activated deoxysugar with cytosine (Scheme
5.2.).
The

fluorination

of

2-O-(trifluoromethylsulfonyl)-1,3,5-tri-O-benzoyl--D-

arabinofuranose (37) has been well established and therefore no attempts to optimize the reaction
were attempted. The crude fluorinated product was used directly without any Sep-Pak®
purification and therefore saving about 10-15 min of time for the step.
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Scheme 5.2. Synthetic scheme for the synthesis of [18F]FAC using TMSOTf assisted coupling of
1,3,5-tribenzoyl-2-deoxy-2-[18F]-arabinofuranose with cytosine silyl ether using microwave
heating.
Coupling of 1,3,5-tribenzoyl-2-deoxy-2-[18F]fluoro-arabinofuranose (39) with cytosine
silyl ether (36) was achieved using 100 µL of trimethylsilyl triflate in acetonitrile. This resulted in
efficient coupling reaction and [18F]FAC was obtained after deprotection. The coupling was
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performed in acetonitrile as solvent as this gave more consistent yields and easier evaporation post
Sep-Pak® purification albeit with higher α-anomeric product. Due to usage of polar CH3CN for
coupling reaction, the undesired -anomer was a major product with - to β-anomer ratio of about
2:19. As demonstrated by Alauddin et al,10 the anomeric ratios are highly dependent on the polarity
of the solvent used for coupling step with non-polar solvents favoring -anomer over -anomer.
Microwave heating was employed as it gave consistent results. Heating the coupling
reaction on a heating block also provided us with the product, albeit in lower yields (<1% d.c.).
However, we did not attempt to optimize coupling reaction with conventional heating.
This method offers an advantage of employing freshly synthesized cytosine silyl ether
(which also employs TMSOTf for protection) without further purification in the synthesis of
[18F]FAC, which in our hands showed considerable increase in the product yields. It was observed
that the product yields were the highest when TMSOTf was used freshly after opening the vial and
the coupling and overall yields declined with storage. This could be attributed to the high reactivity
of TMSOTf that results in hydrolysis of TMSOTf even when all precautions were observed
The HPLC purification of crude product containing a mixture of alpha and beta anomers
was easily accompanied using regular C-18 RP column (250 x 10 mm). Under the given HPLC
conditions (1% acetonitrile in water, 0.1% TFA), [18F]FAC eluted with a retention time of ~17
min preceded by alpha anomer at ~13.5 minutes. For the HPLC purification it is important to
ensure that the crude product is completely free of polar acetonitrile and methanol and
reformulated in 1% acetonitrile in water. Presence of polar solvent can result in elution of product
in dead volume and therefore has to be minimized. Ensuring the evaporation of polar solvents
results in a clean separation of the free fluoride, free sugar, and the α-anomer from the product.
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The crude compound was purified and coinjected with cold FAC on the HPLC to confirm the
identity of the product.
While TMSOTf assisted synthesis [18F]FAC reduces the synthesis time and purification
steps, it has its own drawbacks. It has to be noted that the hydrolysis product triflic acid could be
as corrosive as HBr/AcOH and bromine vapors, products of traditional synthesis. Moreover
TMSOTf is highly reactive and fumes violently in presence of moisture posing handling issues to
untrained personnel. As mentioned earlier, the yield of the final product decreased with storage.
Additionally, the coupling reaction is efficient only using the microwave as very poor yields
resulted using the conventional heating methods.
To summarize the current method that utilizes TMSOTf assisted synthesis of [18F]FAC
reduces the number of steps while providing sufficient yields for carrying out in vivo studies. The
reduction in number of steps is a big advantage for laboratories that lack automated synthesizers
and where manual synthesis is routinely employed.

5.2.1.2

In vitro uptake of [131I]FIAC vs [18F]FAC

In vitro uptake values of [131I]FIAC and [18F]FAC were determined at various time points
after incubation culminating at the end of 2 hours. The activity in the cells from each well was
measured (in counts per minutes, CPM) at each time point on a gamma counter and the results are
expressed as the percentage of total activity added each well (% total CPM).
These experiments revealed time dependent kinetics of in vitro uptake of [18F]FAC, with
an initial rapid phase in both AsPC-1 and MIA PaCa-2 cells that gradually plateaued after 60 min.
Instead, [131I]FIAC showed a more gradual monotonic uptake in vitro. In addition, we observed
102

differences in preferential uptake of the compounds depending on the pancreatic cancer lines, with
[131I]FIAC being up preferentially taken up by AsPC-1 compared to MIA PaCa-2 (Figure 5.2.).

Figure 5.1. Comparison of [18F]FAC and [131I]FIAC uptake in MIA PaCa-2 cells.
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5.2.1.3

PET imaging of in vivo uptake of [131I]FIAC vs [18F]FAC

We measure the in vivo uptake of [131I]FIAC vs [18F]FAC radiolabelled compounds by
PET imaging in mice that developed subcutaneous tumors after xenograft of AsPC-1 and MIA
PaCa-2 cancer cell lines. PET images using [18F]FAC in mice bearing AsPC-1 and MIA PaCa-2
subcutaneous tumors show very low tumor to background differentiation at the end point of 1 h,
in both coronal slices and MIPS [Figure 5.2.]. By 4 h, tumors could be visualized only with limited
demarcation form the background and both, AsPC-1 and MIA PaCa-2 had similar levels of uptakes
(4.45 ± 0.83 and 4.09 ± 0.49 %ID/gPET, ASIPro, maximum pixel value quantification). At this time
point, the spleen and lymph nodes showed higher uptake of [18F]FAC (12.12 ± 5.03 and 9.02 ±
2.15 %ID/g, ASIPro). Similarly, [124I]FIAC did not show high contrast between tumor and
background signal at 4 h p.i. in coronal slices but could be clearly visualized in the MIPS. Staring
at 24 h, the uptake of the compounds in the tumor become more evident, with AsPC-1 showing
clearly a higher uptake of [131I]FIAC than MIA PaCa-2 [Figure 5.3.]. It’s important to note that
the difference in the uptake became more apparent as [131I]FIAC cleared from most of the
background organs and is retained specifically in the tumors. By the end of 24 h the activity seemed
to accumulate in the gut and thyroid. The uptake in lymph nodes or other hematopoietic organs
could not be visualized.
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Figure 5.2. Representative transaxial, coronal slices and maximum intensity projection (MIP,
dorso-ventral projection) of a representative athymic nude mouse bearing subcutaneous tumors
(dorsal view) showing distribution of [18F]FAC uptake in mice at 1h and 4h post i.v. injections in
mice. AsPC-1 is circled with blue-dotted line on the left shoulder while the MIA PaCa-2 is circled
with white dotted line on the right shoulder.

Figure 5.3. Representative PET images of a) [18F]FAC uptake in athymic nude mice at 1h and
4h post i.v. injections and b) [124I]FIAC uptake in athymic nude mice at 4h, 24h, 48h and 72h
post i.v. injections. AsPC-1 is circled with blue-dotted line on the left shoulder while the MIA
PaCa-2 is circled with white dotted line on the right shoulder.
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5.2.1.4

Biodistribution studies

[18F]FAC showed similar uptake in both AsPC-1 and MIA PaCa-2 tumors. [18F]FAC
uptake in AsPC-1 and MiaPaCa-2 xenografts was 6.04 + 0.63 and 5.63 + 0.31 %ID/g (1 h) and
4.45 + 0.93 and 4.10 + 0.55 %ID/g (4 h) (Figure 5.4 and Table 5.1).
In vivo studies revealed the higher uptake of [124I]FIAC in AsPC-1 than MIA PaCa-2
xenografts. While AsPC-1 and MIA PaCa-2 showed an uptake of 1.19 + 0.23 and 0.32 + 0.08
%ID/g (4 h), 0.47 + 0.14 and 0.05 + 0.02 %ID/g (24 h), 0.48 + 0.19 and 06 + 0.008 %ID/g (48 h)
and 0.21 + 0.05 and 0.02 + 0.002 %ID/g (72 h) respectively (Figure 5.5 and Chapter 4, Table
4.3).
It can be clearly seen that the distribution of [18F]FAC and [124I]FIAC is different in the
tumors as well as the organs (Figure 5.5, Supplemental A.5.1). Even though, [18F]FAC shows an
overall higher %ID/g than [124I]FIAC at 4h, there is a significant difference in the uptake between
the tumors and various body organs. The most prominent difference is in the tumors AsPC-1 and
MIA PaCa-2. While [18F]FAC is taken up equally in both tumors, AsPC-1 is taken up in higher
amounts by AsPC-1 when compared to MIA PaCa-2. As noted earlier, even in the repeated trials,
within each mice, AsPC-1 tumors had higher uptake of [131I]FIAC than MIA PaCa-2. Next major
difference is in the lymphopoietic organs such as spleen and lymph nodes. [18F]FAC is taken up
preferentially in spleen and lymph nodes, While radiotracer accumulation could be observed in
spleen and bone in mice injected with [124I]FIAC, lymphopoietic organs were not the major sinks
for the activity. The bones collected along with the bone marrow (another major lymphopoietic
organ) shows higher uptake of radioactivity. As fluoride is highly osteophilic, it cannot be
concluded if the uptake is a result of bone marrow uptake or absorption of free fluoride metabolite.
Other than AsPC-1, the activity seemed to preferentially accumulate in small intestine and
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stomach. This could be attributed to the abundance of sodium/iodide symporter (NIS) in the small
intestine and stomach.11
Moreover, the tumor to organ ratio for [18F]FAC is significantly lower than [124I]FIAC,
which indicates a low tumor to background contrast in PET images (Table 5.2). Despite
[124I]FIAC’s low uptake values, the tracer shows high tumor to organ ratios, indicating good
contrast in the PET images (Figure 5.5.). The difference in the uptake of tracers in AsPC-1 and
MIA PaCa-2 uptake is clearly visible in tumor to background ratios as well. At 4h post injection,
all organs except stomach and large intestine show high tumor to organ ratio. This indicates that
when mice are imaged with [124I]FIAC, tumor (AsPC-1), stomach and large intestine are the only
hotspots in the image. It has to be noted at activity in large intestine decreases rapidly during next
20-70 hours. With [124I]FIAC, higher contrast develops with time as the activity is preferentially
retained in tumor while clearing from other organs. However for [18F]FAC, stomach is the only
organ with significantly higher tumor to organ ratio, while the other organs have tumor to organ
ratios similar to the tumor (AsPC-1) itself. This implies that the activity in the tumor and the organs
surrounding the tumors is comparable or higher than in tumor; which will make the tumor
delineation in the images difficult. As noted before, longer imaging time in [18F]FAC are limited
because of 109.7 min half-life of fluorine-18.
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Figure 5.4. Biodistribution of [18F]FAC in AsPC-1 and MIA PaCa-2 subcutaneous tumor bearing
athymic nude mice at 1 and 4 post i.v.injection
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1h

4h

Blood

3.71 ± 0.09

2.36 ± 0.42

AsPC-1

6.03 ± 0.56

4.45 ± 0.83

MiaPaCa-2

5.62 ± 0.27

4.09 ± 0.49

Heart

4.78 ± 0.26

2.79 ± 0.55

Lungs

3.45 ± 0.22

2.18 ± 0.49

Liver

4.12 ± 0.14

2.69 ± 0.37

Spleen

16.44 ± 2.72 12.12 ± 5.03

Stomach

2.43 ± 0.47

0.82 ± 0.29

S. Intestine

5.66 ± 0.42

3.82 ± 0.68

L. Intestine

2.4 ± 0.13

2.44 ± 0.46

Kidneys

4.25 ± 0.15

2.36 ± 0.59

Muscle

3.89 ± 0.32

2.55 ± 0.61

Bone

7.87 ± 1.12

7.35 ± 1.72

Lymph nodes

8.03 ± 1.39

9.02 ± 2.15

Table 5.1. Numerical values of Biodistribution of [18F]FAC in AsPC-1 and MIA PaCa-2
subcutaneous tumor bearing athymic nude mice at 1 and 4 post i.v.injection
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AsPC-1 tumor to organ ratio
1h

4h

Blood

1.63

1.88

AsPC-1

1.00

1.00

MiaPaCa-2

1.07

1.09

Heart

1.26

1.59

Lungs

1.75

2.04

Liver

1.46

1.65

Spleen

0.37

0.37

Stomach

2.48

5.42

S. Intestine

1.07

1.16

L. Intestine

2.51

1.82

Kidneys

1.42

1.89

Muscle

1.55

1.74

Bone

0.77

0.61

Lymph nodes

0.75

0.49

Table 5.2. Tumor to organ ratios of [18F]FAC in the mouse organs
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[131I]FIAC AsPC-1:Organ ratio
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[18F]FAC AsPC-1:Organ ratio
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Figure 5.5. [18F]FAC and [131I] FIAC in vivo uptake comparison tumor-organ ratio
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5.2.2

Further in vitro evaluation of [131I]FIAC to further evaluate
[131I]FIAC as a marker for gem

In vitro and in vivo uptake of [131I]FIAC clearly showed that the kinetics of uptake and
distribution of [131I]FIAC are significantly different from [18F]FAC, a tracer previously evaluated
as a probe for dCK. To further the investigation toward discovering the various enzymes that could
be playing a potential role in the differential uptake of FIAC further experiments were performed
which are discussed in this section.
To eliminate the role of nucleoside transporters in the uptake of the radioactive tracers, a
glioma cell line (U87) transfected with plasmids that overexpress various enzymes were used.
Transfected cell lines were generously provided by the Ponomarev lab at MSKCC and their
generation is described in detail elsewhere.12 The wild type cells (U87-wild) cells were transfected
to overexpress dCK (referred to as U-87 dCK in the text), herpes simplex virus - thymidine kinase
(referred to as U87-HSV-TK in the text), or human thymidine kinase-2 (referred to as U87-TK2
in the text). Non-transfected cell lines or the wild types were used to evaluate the baseline
expression of the enzymes. U-87 dCK cell lines were modified to overexpress deoxycytidine
kinase, the rate limiting step in the metabolism of deoxycytidine and gem as discussed in the
previous chapters. U87-HSV-TK cell lines overexpressed Herpes Simplex Virus Type 1 thymidine
kinase which has been widely used in the reporter gene research. HSV-TK1 phosphorylates
various uracil derivatives such as 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodouridine
(FIAU) and acycloguanosine analogs. U87-TK2 cells overexpressed thymidine kinase 2 which is
naturally expressed in human mitochondria and specifically phosphorylates thymidine,
deoxycytidine and deoxyuridine. Along with these two cell lines two other pancreatic cell lines
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BxPC-3 (epithelial adenocarcinoma) and PANC-1 (epithelial carcinoma) were also added to the
panel.
5.2.2.1

Comparison of [131I] FIAC uptake in a pancreatic cancer cell
lines AsPC-1 and MIAPaCa-2

Once it was confirmed that FIAC could be phosphorylated by dCK, we set out to test its
differential uptake in cells showing different sensitivity to gem. In that effort, AsPC-1 and MIA
PaCa-2 cell line were chosen. AsPC-1 and MIA Paca-2 cells are one of the most widely used cells
for conducting experiments involving pancreatic cancer cell lines. A brief literature review
revealed that while all the researchers agreed that these cell lines respond differently to gem, there
has been no consensus on which of them is more sensitive to gem treatment. While some studies
claim that MIA PaCa-2 cells are dramatically more sensitive to gem treatment than AsPC-1,13
there are equal number of reports that suggest otherwise or that both cells are equally sensitive to
gem treatment (supplemental Table A.5.2).14-18 Such dramatic difference in literature can be
attributed to non-uniformity in the experimental methods. Between the reported studies the
incubation time varies from 24 h to 72 h. Also, there is a wide variety of reagents that are available
to test the cell viability. Thus, we verified the response of these cell to gem treatment in vitro.
Briefly the cells 5 × 103 were incubated in a 96 well plate with different concentration of
gem ranging from 1 pM to 10 mM for 72h. At the end of 72h, the viability of cells in each well
was assessed using MTT reagent. MIA PaCa-2 (5.46 nM) cells were more sensitive to gem
treatment than AsPC-1 (520 nM) (Figure 5.6.). Even at the highest concentration of gem, AsPC1 showed a mere 30% inhibition reduction in viability while almost all the MIA PaCa-2 cells
succumbed to the treatment. Repeated assays reflected similar results.
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Figure 5.6. Dose–response curve of cell lines AsPC-1 and MIAPaCa-2 after 72 h incubation
with gemcitabine showing complete growth inhibition in MIAPaCa-2 and only 45 % growth
inhibition at the highest concentration.

Once it was determined that AsPC-1 were less sensitive to gem than MIA PaCa-2, time
dependent cell uptake assays were performed using [131I]FIAC, which was the only substrate that
showed uptake in AsPC-1 cells and was phosphorylated by dCK. Cellular uptake assays showed
that [131I]FIAC was taken up preferentially (4X) by AsPC-1 in comparison to MIA PaCa-2 cell
lines (Figure 3.3.).
Despite being a substrate for dCK, the preferential uptake of [131I]FIAC in AsPC-1
compared to MIA PaCA-1 does not correlate with their sensitivity to gem treatment as assessed
by viability assay of cells. As observed in the MTT viability assay, MIA PaCa-2 cells were more
sensitive to the gem. Therefore, it was expected that [131I]FIAC would be taken in higher amounts
by the MIA PaCa-2 than AsPC-1 to reflect their sensitivity to gem.
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5.2.2.2

Cell uptake studies with additional cell lines

Radio-iodinated product [131I]FIAC were synthesized as described in chapter 2, pure
fractions were collected from HPLC, their identity confirmed by co-elution with their respective
non-radioactive compounds. [3H]-Gem was obtained commercially. The radioactive analogs were
diluted with phosphate buffered saline (PBS) and used for further in vitro experiments. In vitro
kinetic uptake assay was performed on 8 different using 1 million cells with radiolabeled drug
(0.5-1 µCi (18.5-37 kBq for [131I]FIAC and 0.05-0.1 µCi (1.85-3.7 kBq for[3H]-Gem) for 2h. The
cells were harvested on a Brandel harvester and the filters counted on a gamma counter for Iodine131 and dispersed in scintillation liquid and counted on beta counter for tritium. Radioactivity in
the collected cells was measured as an indication of uptake of radioactive substrates. Due to the
difference in the cell lines and different radioactive sources all the activities were normalized to
the weight of total protein in the cells and expressed as the percentage of total counts (in media)
taken up by the cells per microgram of protein.
U-87 cells transfected with dCK clearly take up almost 3 times the amount of [3H]-Gem
than the U-87 wild type cells (Figure 5.6 a). While there is a significant increase in the [131I]FIAC
uptake by U87-dCK cells compared to U-87 wild type cells, the uptake levels in U87-dCK are
dwarfed by the uptake in both U-87 HSV-TK and U87-TK2 cells. In these transfected cell lines
where the specific enzymes are overexpressed while keeping the other enzymes and transporters
constant, provide us with an estimate of affinity of the radioactive compounds for the specific
overexpressed enzyme. [3H]-Gem is preferentially retained in the cells overexpressing dCK while
being taken up in other cell lines in the background levels; indicating that [3H]-Gem is a substrate
for dCK and not for HSV-TK or TK2. [131I]FIAC uptake pattern is remarkably different from [3H]Gem and it appears to be a better substrate for TK2 > HSV-TK > dCK. It has to be noted that these
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results agree the phosphorylation assay describe in section 3.2.4, which indicates that [3H]-Gem is
a much better substrate for dCK than [131I]FIAC. Nonetheless, it is proven again that [131I]FIAC is
a substrate for dCK albeit with lower affinity.
Similar to transfected U87 cell lines, the uptake pattern of [131I]FIAC in pancreatic cell
lines is different when compared to [3H]-Gem. While [3H]-Gem is take up equally in AsPC-1 and
MIA PaCa-2 (similar to [18F]FAC), [131I]FIAC shows higher uptake in AsPC-1 than MIA PaCa-2.
(Figure 5.6 b). These uptake of [131I]FIAC in AsPC-1 and MIA PaCa-2 is consistent with previous
results. When the panel for the pancreatic cancer cell lines is extended, there is a variation in the
levels of transporters and enzymes which is responsible for differences in the metabolism of
various molecules based on their specificity of enzymes. If a radioactive molecule is a true tracer
for a drug, it should exhibit similar uptake as the drug, which is clearly not true for the panel of
pancreatic cancer cell lines. These preliminary uptake results indicate that [131I]FIAC and [3H]Gem do not share the same affinity for various enzymes in the cell.
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Figure 5.6. Comparison of a) [3H]-Gem and b) [131I]FIAC uptake in various cell lines.
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5.2.2.3.

Evaluation of mRNA levels using RTPCR

While the cell uptake results provide an estimate of the radiotracer uptake in various cell
lines, they do not show the extent to which dCK is expressed in the cells. Moreover, while the
uptake of [3H]-Gem could be correlated to the levels of dCK in transfected cell lines, not much is
known about the levels of these enzymes in the pancreatic cancer cell lines used. It could also be
observed that [131I]FIAC did not show any similarity to uptake of [3H]-Gem. To gain a better
understanding of the uptake assay in relation to the dCK levels, levels of dCK at both transcript
(mRNA) and protein level were assessed in all the cell lines.
mRNA levels in various cell lines were evaluated using RTPCR. AsPC-1 cells had had
1.25-fold higher levels of mRNA coding for dCK than MIA PaCa-2 [Figure 5.7.]. While the
mRNA levels in U-87 dCK are approximately 300 times higher than the mRNA coding for dCK
in U87-wild type cells, the levels of mRNA do not correspond to the fold increase in the uptake of
[3H]-Gem. Interestingly, the levels of [131I]FIAC uptake seem to correspond the to the mRNA
levels in AsPC-1 and MIA PaCa-2. Confoundingly though, the of [3H]-Gem uptake in vitro follows
the levels of mRNA in both U-87 cells and pancreatic cell lines except for AsPC-1 and MIA PaCa2. Regrettably, the uptake of [131I]FIAC does not match mRNA levels across the panel.
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Figure 5.7. dCK mRNA expression levels in various cell lines either normalized to U-87 wild
for the transfected cell lines and to AsPC-1 for the pancreatic cancer cell lines by RT-PCR

5.2.2.4

Evaluation of protein levels using western blots

While mRNA levels are a good indication of protein levels, it is essential to estimate the
protein levels in cells independently. The levels of dCK were found to be high in U87-dCK cells
when compared to the wild type cells. In both U87-dCk and U-87 TK2 cells, intense bands appear
approximately at twice the molecular weight of dCK. While these bands could be the dimers of
dCK, the appearance of band in U-87 TK2 cells is puzzling. Unlike mRNA levels, dCK protein
levels were found to be similar in both AsPC-1 and MIA PaCa-2 (1 vs 0.99, normalized to β-actin),
while the levels of dCK were found to be elevated in BxPC-3 and PANC-1 compared to AsPC-1
and MIA PaCa-2. [Figure 5.8.].
The uptake of [3H]-Gem reflects the levels of dCK in various cell lines. While the uptake
of [3H]-Gem was significantly higher in U87-dCK, the results do not scale to the levels of dCK
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protein. Similar difference in the uptake vs the protein-level can be observed in BxPC-3 cells as
well. While both, BxPC-3 and PANC-1 cells express similar levels of dCK, [3H]-Gem uptake in
BxPC-3 is higher than in PANC-1 cells. The uptake of [3H]-Gem reflects the levels of dCK in
AsPC-1 and MIA PaCa-2 and other cells as well.
Alternatively, [131I]FIAC uptake in the cells does not follow the levels of dCK in
cells. However, the higher levels of uptake [131I]FIAC in U-87 dCK cells corresponds with the
higher levels of dCK expression in the cells. It should also be noted that the mRNA levels do not
translate to the protein levels seen in the western blots. Unfortunately, the uptake of [131I]FIAC
does not match either the dCK protein levels or mRNA levels across the entire panel of cells.

Figure 5.8. Western blots showing the level of dCK and β-actin in various cancer cell lines
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5.3

Conclusions
An alternative shorter method for synthesis of [18F]FAC is developed. Overall synthesis

was shortened by eliminating the bromination and evaporation steps and by employing microwave
heating for the coupling of deoxysugar with the cytosine. This method provides reliably
reproducible yields and is easily amenable for manual synthesis.
We compared [124I]FIAC to [18F]FAC as PET imaging agents in mice bearing two
subcutaneous pancreatic tumors AsPC-1 and MIA PaCa-2 of similar size and found that [124I]FIAC
shows remarkably different pharmacokinetics and bio distribution in mice than known dCK
imaging agent, [18F]FAC. [124I]FIAC and [18F]FAC were synthesized and compared for their
efficacy to serve as potential biomarker for gemcitabine response in pancreatic cancer models in
vitro and in vivo. Preliminary studies indicated that [124I]FIAC and [18F]FAC behave differently in
these models with former showing preferential uptake in AsPC-1 cells and xenografts. Distribution
of [124I]FIAC was very distinct from [18F]FAC. While [124I]FIAC showed higher uptake in AsPC1 than MIA PaCa-2, [18F]FAC showed similar uptake levels in both the tumor types. Key lymphoid
organs, spleen and the nodes, show a high uptake of [18F]FAC almost similar %ID/g as the tumors.
While [124I]FIAC shows high uptake in spleen, the uptake is quite low in lymph nodes. Such
difference in the selective uptake in spleen but not in lymph nodes confounds us.
Comparing the in vitro uptake of [124I]FIAC to [3H]-Gem and evaluating the levels of dCK
levels in various kinds of cells does not provide any concrete insight into the mechanism of action
of [124I]FIAC. Thus we conclude that [124I]FIAC might not be the right tracer act as a biomarker
for gem response.
In vitro, [131I]FIAC was taken up in differential amounts in cells lines, AsPC-1 and MIA
PaCa-2, expressing similar levels of dCK and mRNA levels. [18F]FAC shows similar uptake in
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both AsPC-1 and MIA PaCa-2 cell lines which corresponds to the relative of protein levels of
dCK. Nevertheless, the sensitivity of AsPC-1 and MIA PaCa-2 to gem in vitro, as determined by
MTT assay, could not be related either to [3H]-Gem, [18F]FAC or [124I]FIAC uptake.
These preliminary results reinforce the view of a complex mechanism of action regulating
the uptake of gem and FIAC and we predict that the response to gemcitabine is controlled beyond
the levels of dCK. While we concentrated on dCK because of its rate-limiting nature in the gem’s
metabolic pathway, other enzymes such as ribonucleotide reductase and deaminase need to be
studied in depth. Further experiments are needed to elucidate the mechanism of action of those
compounds. Given the difference in the in vitro uptake of [18F]FAC, [124I]FIAC and [3H]-Gem
and the fact that the [18F]FAC or [124I]FIAC radiolabeling of pancreatic tumors does not strictly
depends on dCK expression levels in the tumors, predicting the responders vs non-responders
seems highly improbable using [18F]FAC or [124I]FIAC. However, while the use of [18F]FAC or
[124I]FIAC to differentiate responders vs non-responders to gem therapy might be challenging, we
noted a significant high tumor to background ratios and high selectivity of [ 124I]FIAC in tumors,
which makes [124I]FIAC a better PET probe for pancreatic tumor detection in general . Given such
favorable characteristics, we proceeded to confirm [124I]FIAC as an imaging agent for pancreatic
cancers by performing further in vivo experiments.
5.4

Experimental:
5.4.1

General methods and materials

All reagents and solvents were obtained from Sigma-Aldrich or Thermo Fisher Scientific
and used without further purification. Carrier-free [18F]fluoride in water was obtained from the
Radioisotopes and Molecular Imaging Probes core facility at MSKCC. FAC was purchased from
Carbosynth,

Berkshire,

UK

(CAS:

56632-83-8,

Product

code:

ND08343).

2-(O)122

(trifluoromethylsulfonly)-1,3,5-tri-O-benzoyl--D-arabinofuranose (4) was purchased from
Carbosynth, Berkshire, UK (CAS: 97614-41-0, Product code: MT07900). Sep-Pak Accell Plus
QMA Plus Short Cartridge, 360 mg Sorbent per Cartridge, 37-55 µm Particle Size, (WAT020545)
were purchased from Waters (MA, USA). C18-mini column (Strata C18-E (55 µm, 70 Å)
50mg/1mL) [8B-S001-EAK] were purchased from Phenomenex®, CA. HPLC purification and
analysis were performed on a Shimadzu HPLC system equipped with a binary high-pressure
gradient solvent delivery module LC 10A and SPD-20A UV dual wavelength detector connected
to a bioscan flow-count radio-HPLC detector system for gamma detection. Crude products were
purified and analyzed for purity on reversed phase C18 column using Waters XBridge™ 5 µm, 10
x 250 mm [186008167] (for preparative scale) and Phenomenex® Gemini 5 µm, 250 x 4.6 mm
110 Å [00G-4435-E0], (for analytical HPLC). Purification was carried out using an isocratic
solvent system of 1% acetonitrile in 0.1% trifluoroacetic acid at a flow rate of 4 mL/min. Analysis
of the purified product was carried out using 3% acetonitrile in 0.1% trifluoroacetic acid at a flow
rate of 1 mL/min. Microwave systems used for the reactions were obtained from Biotage Inc
(Initiator 2.5, Charlotte, NC).
5.4.2. Synthesis of [18F]FAC (2′ -deoxy-2′-[18F]-fluoro--D-(arabinofuranosyl)cytosine) (21).
Overall synthetic strategy is given in Scheme 5.2. The synthetic approach was based on our earlier
method for synthesis of FIAU and its analogs originally developed by Vorbruggen and optimized
for pyrimidine nucleosides.19 Synthetic scheme consists of four major steps as described below.
5.5.2.1

Synthesis

of

cytosine

silyl

ether

(N-(trimethylsilyl)-2-

((trimethylsilyl)oxy)pyrimidin-4-amine, 36): Cytosine silyl ether (36) was synthesized by
heating a mixture of cytosine (42) 12 mg (0.11 mmoles), TMSOTf (100 µL, 123 mg, 0.55
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mmoles), and 1,1,1-Trimethyl-N-(trimethylsilyl)silanamine (HMDS, 100 µL, 0.47 mmoles) in
acetonitrile (300 µL) at 120 °C for 20 min in a microwave vial. The product was used for coupling
reaction, without any further purification.
Synthesis of 2-deoxy-2-[18F]-fluoro-1,3,5-tri-O-benzoyl--D-

5.5.2.2

arabinofuranose (39) (Fluorination of 2-O-[(Trifluoromethyl)sulfonyl]-1,3,5-tri-O-benzoylα-D-ribofuranose (37))

18

F in the form of [18F]HF, was loaded onto QMA cartridge

preconditioned by passing 5 mL of 0.25 M KHCO3 followed by 20 mL of deionized water and
eluted with 1 mL of 90% acetonitrile containing KHCO3 (1.6 mg, 15.9 µmol) and kyrptofix (10
mg, 26.4 µmol) into a 10 mL reacti-vial™. The water acetonitrile azeotrope was removed by
heating the vial to 105 - 110 °C under a slow stream of argon gas (150-175 mL/min). To the dried
reacti-vial™, an additional 0.7 mL of anhydrous acetonitrile was added, and the solvent was
removed as described above and the whole process was repeated 2 additional times. The reactivial™ was cooled to r.t. and radioactivity was extracted using anhydrous acetonitrile (0.4 mL)
and added to 2-O-(trifluoromethylsulfonyl)-1,3,5-tri-O-benzoyl--D-arabinofuranose (4) (15 mg)
in a sealed microwave vial and the reaction mixture was heated at 120 °C for 30 minutes. The
product was used for reactions without any further purification.
5.5.2.3

Synthesis

of

3′,5′-O-dibenzoyl-(2-[18F]-fluoro--D-

(arabinofuranosyl) cytosine (40) (Coupling of cytosine silyl ether (36) and 2-deoxy-2-[18F]fluoro-1,3,5-tri-O-benzoyl--D-arabinofuranose(39)): The reaction mixture was cooled to RT
and added to vial containing silyl ether (36) solution and TMSOTf (100 µL) and HMDS (100 µL)
in acetonitrile (300 µL) and the reaction mixture was heated to 120 °C for 25 min using microwave
reactor under sealed conditions. Then reaction mixture was cooled to RT and passed through a
silica Sep-Pak® plus column (pre-conditioned with 5 mL of hexane) and eluted into a 10 mL reacti124

vial™ with 10% MeOH in CH2Cl2 (2 x 1.25 ml). The solvents were removed by heating the reactivial™ under argon flow at 100 °C and used for the next step directly.
5.5.2.4

Deprotection

of

3′,5′-O-dibenzoyl-(2-[18F]-fluoro--D-

(arabinofuranosyl) cytosine (40) To the vial containing 8, 0.5 mL of 4.6 M sodium methoxide in
MeOH (25% w/v) was added and the reaction mixture was heated at 80 °C for 10 min for
deprotection of the benzoyl groups. The reaction mixture was treated with glacial acetic acid (120
µL) and the solvent was removed under argon stream at 80 °C. The residue was formulated in 1%
acetonitrile and passed through C18-mini column (Strata C18-E (55 µm, 70 Å) 50mg/1mL) to
remove insoluble impurities. The crude product was purified using reversed phased HPLC (on the
preparative column) using an isocratic solvent system of 1% acetonitrile in 0.1% trifluoroacetic
acid in water. The radioactive fraction corresponding to the product peak [18F]FAC (21, β-anomer)
was collected and solvent evaporated under reduced pressure. The identity of the product [18F]FAC
(21) was verified by co-injecting with commercially available non-radioactive analog on an HPLC
analytical column using an isocratic solvent system of 3% acetonitrile in 0.1% trifluoroacetic acid
in water.
5.4.3

Western Blots

Anti-dCK antibody was purchased from Millipore Sigma (Cat: MABC188) and
dCK levels were quantified and normalized to β-actin levels. Western blotting was performed as
published before.20
5.4.4

cDNA and qPCR

Quantitative real-time PCR were performed on mRNA harvested using commercial
kit (79656 and 74104, Qiagen). Reverse transcription was performed using commercial kit
(4368813, Applied Biosystems).

dCK and TK2 primers for qPCR were purchased from
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SAbiosciences. Sybr Green qPCR Mastermix for qPCR were obtained commercially (330529,
Qiagen).
5.4.5

Xenograft models:

6-8 week old female athymic nude mice (Hsd:Athymic Nude-Forxn1nu) were
obtained from Envigo RMS, Inc. (Indianapolis, IN), and were allowed to acclimatize at least for 1
week. All animal studies were reviewed and approved by MSKCC’s Institutional Animal Care and
Use Committee (protocols 86-02-020 and 08-07-013) and followed the National Institute of Health
guidelines for animal welfare.
5.4.6

In vivo Animal PET imaging and Biodistribution:

PET images were obtained with the mice under anesthesia in medical air (2 L/min,
2% isoflurane, Baxter Healthcare, Deerfield, IL, USA) either on Focus 120 microPET (Concorde
Microsystems, Knoxville, TN) or Inveon PET-CT (Siemens, TX, USA). All images are either
analyzed by ASIPro VM (Concorde Microsystem) or INVEON research workspace (Siemens).
Using ASIPro, maximum pixel value was recorded for tumors. Post-reconstruction smoothing was
applied for visual representation of images in the figures. Mice and euthanized by CO 2
asphyxiation at predetermined time points and organs were harvested. Activity in syringe prior to
injection and after injection was used to determine the total activity administered referred to as
injected dose (ID). Activity in the collected organs was measured on WIZARDTM 3” 1480 gamma
counter (Perkin Elmer, Waltham, MA, USA). Count data were background and decay-corrected
to the time of injection and %ID/g for all the organs was calculated by weighing the organs. The
average and standard deviation of the %ID/g was determined using Graphpad Prism version 6.07
for Windows (Graphpad software, San Diego, CA, USA, www.graphpad.com).
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5.4.7

Cell viability assay (MTT assay)

MTT assay was performed as suggested by the kit manual. Briefly, 5× 103 cells in 100 µL
media were plated in each well of a 96 well plate. Different dilutions of gemcitabine (drug),
ranging from 1 mM to 1pM, were added to wells in triplicate. The cells were incubated for 72 h
with drug and MTT assay reagent was added at the end of 72 h. Cells were incubated with the
MTT reagent for 4 h and were incubated in lysis buffer (provided in MTT assay kit) overnight.
Cell absorbance was read the next day at 550 nm and background was read at 690 nm. Percentage
of viability was calculated from the absorbance plotted against concentration of the drug
concentrations to determine the EC50 values using non-linear regression in PRISM (robust fit).
5.4.8

In vivo microPET/CT Imaging

β-[18F]FAC (150-200 µCi) (1) reconstituted in 0.9 N saline was injected iv into
athymic nude mice bearing ASPC-1 and MIAPACA-2 tumors on fore limbs. The animals were
imaged 1h and 4h post injection on Inveon MicoroPET. Sequential studies with the radiolabeled
molecules were performed on the same animals.
5.4.9

Ex vivo Biodistribution.

β-[18F]FAC (25-30 µCi) (1) reconstituted in 0.9 N saline was injected iv into
athymic nude mice bearing ASPC-1 and MIAPACA-2 tumors on fore limbs. Mice (n=4-5 per
group) were euthanized at 1h and 4h and organs were harvested. The activity in them was
measured on gamma counter. The counts were normalized to the weights of organ and expressed
as %ID/g
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS
6.1

Summary

Gemcitabine is the first line of therapy used to treat pancreatic cancers. Only a quarter of
patients respond to therapy and the reasons for such dismal prognosis are unknown. It has been
hypothesized that dCK is a rate-limiting key enzyme responsible for the cytotoxic effect of gem
and that levels of dCK could predict the response of a patient to gem. Thus, developing a noninvasive biomarker to predict the levels of dCK could help the oncologists to differentiate
responders from non-responders and help optimize therapy. Three probes FIRC, FIAC and IGem
were designed based on in silico modeling to assess their affinity for dCK. A satisfactory synthetic
approach was developed and the efficacy of [131I]FIRC, [131I]IGem and [131I]FIAC as a surrogate
marker of dCK levels was evaluated. In vitro uptake assays in various cell lined confirmed that
only [131I]FIAC was taken up by cells. Therefore, further assays were performed on [131I]FIAC (or
its PET active analog). In vitro phosphorylation of [124I]FIAC by dCK in presence of ATP was
slow and inefficient as determined by polyethylimmine (PEI) impregnated cellulose TLC plates.
Despite the mediocre affinity of FIAC for dCK, we hypothesized that the clear visualization of
tumors would be possible because of the specific accumulation in target organs and clearance form
target organs; which could be imaged for longer periods of time the long half-life of the
radioiodine. In vitro and in vivo, radioiodine labeled FIAC was taken up in higher amounts in
AsPC-1 cell lines compared to MIA PaCa-2. These results were in direct contradiction to their in
vitro sensitivity to gem. In vivo PET imaging in mice bearing pancreatic cancer tumors, [124I]FIAC
showed selective retention in tumors while clearing from non-target organs. [18F]FAC, a known
substrate for dCK, shows similar uptake in both AsPC-1 and MIA PaCa-2 cell lines which
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corresponds to the relative of protein levels of dCK. Nevertheless, the sensitivity of AsPC-1 and
MIA PaCa-2 in vitro, as determined by MTT assay, could not be correlated either to [18F]FAC or
[124I]FIAC uptake. The results attained so far suggest that despite dCK being a critical enzyme in
the gem’s mechanism of action, the sensitivity of cancers to gem is governed a complex interplay
of enzymes in addition to dCK.
6.2

dCK and its potential as a target for imaging cancers

While dCK has been implicated as the key enzyme in the mechanism of action of gem, the
results of these experiments confirm that the levels of dCK in AsPC-1 and MIA PaCa-2 do not
directly correspond to the response to gem treatment in vitro. Various researchers have published
similar results suggesting that the sensitivity of cells to gem is not solely governed by dCK. A
retrospective analysis of various biomarkers involving 229 patients showed that dCK was not
associated with survival in gemcitabine treatment.1 Another study by same group showed that
HENT1 expression was associated with overall and disease free survival in group of patients
treated with gem in a 538 patient sample.2 In a different study, it was reported that
immunohistochemical expression of DCK protein in tumors was not significantly correlated with
the survival of NSCLC patients treated with gemcitabine-based chemotherapy.3 While the dCK
is a prognostic marker for response to gem treatment, various other prognostic markers have been
studied and reviewed extensively.4 Thus, a holistic approach is needed to study the interplay of
various enzymes conferring sensitivity and resistance to gem treatment.
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6.3

Future directions:
6.3.1

Optimization of synthetic methodologies

Isolated radiochemical yields of radioiodine labeled nucleoside analogs were adequate to
perform the in vitro and in vivo experiment but low. To increase the yields of radioiodinated gem
analogs, our attempts towards making trimethyltin precursor using FIRC as a model reaction were
unsuccessful. While the unprotected hydrogens of amino and the hydroxyl groups are not expected
to be labile and similar reactions were achieved using a uridine precursor, it is expected that
protecting the hydrogens could give us an access to the tin precursor. Reactions were not optimized
further.
The overall low yields of product are a result of low-labeling efficiencies of both I-131 and
I-124 in the given electrophilic aromatic substitution and high losses during purification on HPLC.
Additionally, almost 25-40% of radioactive iodine cannot be recovered from the reaction
tubes/vials. While the losses to the reaction vessels are difficult to mitigate, the losses because of
the inefficient reaction conditions can be mitigated by synthesizing efficient precursors with good
leaving groups at 5-position which could facilitate rapid substitution. Examples of such groups
being trimethyl tin, tributyl tin or boronate esters. Such efficient reactions with almost quantitative
radiochemical yields have been demonstrated and applied to the synthesis of various nucleoside
analogs.5
6.3.2

Potential use of radiolabeled use of FIAC as radiotherapeutic

Radioactive iodine therapy is well known in the treatment of various thyroid cancers.6-9
Along with iodine-131, iodine-123 and iodine-125 have been studied for their radiotoxicity and
their potential to be used in radiopharmaceutical design.10 Use of radioactive iodide has been
limited in treatment of cancers other than those related to thyroid because of its selective
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accumulation in thyroid and non-selective uptake in other organs. Therefore, molecules that can
selectively deliver radioactive iodine to selected targets such as tumors could be used for
radiotherapy.
We have demonstrated that radioactive iodine is selectively taken up in tumors and cleared
from the organs. Within the tumor FIAC accumulated in the DNA. Thus, we hypothesize that
radioiodine labeled FIAC could be potentially used in radiotherapy in the treatment of tumors with
or without gem therapy. Such increase in the therapeutic window because of longer-lived isotope
and specificity toward the tumor cells could be used in radiotherapy.
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APPENDIX
Chapter 1

Scheme A.1.1 Proposed mechanism of deoxodifluorination using [18F]fluoride and DAST as
additional fluoride source to synthesize [18F]gemcitabine
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Chapter 2

Figure A.2.1 1H NMR 2′-Fluoro-2′-deoxy-1- β -D-ribofuranosyl-5-iodocytosine (FIRC).
Spectra were collected on a Bruker 500 MHz spectrometer in DMSO
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Figure A.2.2 2′-Fluoro-2′-deoxy-1-β -D-ribofuranosyl-5-iodocytosine (FIRC) low resolution
mass spectrum indicating expected [M+H]+ (MS+) m/z of 372.14. The low-resolution mass
spectrum was recorded using a Waters Acquity UPLC with electro-spray ionization (ESI) SQ
detector.
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Figure A.2.3 2′-Fluoro-2′-deoxy-1-β-D-arabinofuranosyl-5-ribocytosine (FIRC) low resolution
mass spectrum indicating expected [M+H]+ (MS+) m/z of 371.98. The low-resolution mass
spectrum was recorded using a Waters Acquity UPLC with electro-spray ionization (ESI) SQ
detector.
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Figure A.2.4 1H NMR of 2,2′-difluoro-2-deoxy-5-iododcytidine (5-iododgemcitabine, IGem).
Spectra were collected on a Bruker 500 MHz spectrometer in DMSO

136

Figure A.2.5 2,2′-difluoro-2-deoxy-5-iododcytidine
(5-iododgemcitabine,
IGem)
low
resolution mass spectrum indicating expected [M+H]+ (MS+) m/z of 389.9. The low-resolution
mass spectrum was recorded using a Waters Acquity UPLC with electro-spray ionization (ESI)
SQ detector.
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Figure A.2.6 High resolution mass spectrometry (HRMS) analysis of the 2,2′-difluoro-2deoxy-5-iododcytidine (5-iododgemcitabine, IGem) showing the expected mass signal.
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Figure A.2.7 1H NMR 2′-Fluoro-2′-deoxy-1- β -D-arabinofuranosyl-5-iodocytosine (FIAC).
Spectra were collected on a Bruker 500 MHz spectrometer in DMSO
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Figure A.2.8 Liquid chromatogram component of LCMS acquired on waters acquity ultra
performance LC with electrospary ionization SQ detector.
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Figure A.2.9 2′-Fluoro-2′-deoxy-1-β -D-arabinofuranosyl-5-iodocytosine (FIAC) low resolution
mass spectrum indicating expected [M+H]+ (MS+) m/z of 372.14. The low-resolution mass
spectrum was recorded using a Waters Acquity UPLC with electro-spray ionization (ESI) SQ
detector.
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Figure A.2.10 High resolution mass spectrometry (HRMS) analysis of the 2′-deoxy- 2′-Fluoro2′-deoxy-1- β -D-arabinofuranosyl-5-iodocytosine (FIAC) showing the expected mass signal.
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Chapter 3:

Figure A.3.1 Uptake of [131I]FIRC compared to [131I]FIAC in Jurkat cells.

Figure A.3.2 Uptake of [131I]FIAC in U87- wild and U-87 dCK transfected cell lines showing
a meager yet higher uptake in U-87 dCK transfected cell lines. See chapter 6 for the description
of cell lines.
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Chapter 4:
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Figure A.4.1 Biodistribution of [131I]FIAC in AsPC-1 and MIA PaCa-2 subcutaneous tumor
bearing athymic nude mice at 4, 24, 48 and 72 post i.v. injection.
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4h

24h

48h

72h

Blood

0.377 ± 0.36

0.255 ± 0.30

0.384 ± 0.36

0.019 ± 0.02

AsPC-1

0.177 ± 0.13

0.137 ± 0.16

0.237 ± 0.18

0.155 ± 0.25

MIA PaCa-2

0.149 ± 0.13

0.094 ± 0.10

0.144 ± 0.12

0.012 ± 0.02

Heart

0.126 ± 0.10

0.071 ± 0.08

0.106 ± 0.09

0.012 ± 0.00

Lungs

0.277 ± 0.26

0.180 ± 0.20

0.229 ± 0.21

0.005 ± 0.00

Liver

0.138 ± 0.12

0.093 ± 0.11

0.140 ± 0.13

0.001 ± 0.00

Stomach

3.430 ± 4.10

1.910 ± 2.18

3.228 ± 2.70

0.003 ± 0.00

Spleen

0.115 ± 0.10

0.090 ± 0.10

0.120 ± 0.10

0.059 ± 0.05

Sm. Intestine

0.119 ± 0.10

0.091 ± 0.08

0.139 ± 0.10

0.002 ± 0.00

Lg. Intestine

0.209 ± 0.09

0.144 ± 0.12

0.190 ± 0.15

0.000 ± 0.00

Kidney

0.191 ± 0.16

0.141 ± 0.16

0.224 ± 0.22

0.044 ± 0.03

Muscle

0.047 ± 0.04

0.026 ± 0.03

0.038 ± 0.03

0.029 ± 0.01

Bone

0.140 ± 0.13

0.086 ± 0.10

0.115 ± 0.09

0.044 ± 0.03

Tail

0.298 ± 0.14

0.144 ± 0.14

0.203 ± 0.16

0.000 ± 9.82

Lymph Nodes

0.102 ± 0.10

0.070 ± 0.06

0.117 ± 0.10

0.008 ± 0.00

Thyroid

0.260 ± 0.16

0.154 ± 0.13

0.274 ± 0.20

0.239 ± 0.16

Table A.4.1 Biodistribution of [131I]FIAC in AsPC-1 and MIA PaCa-2 subcutaneous tumor
bearing athymic nude mice at 4, 24, 48 and 72 post i.v. injection.
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Chapter 5:

Figure A.5.1 Biodistribution of a) [18F]-FAC and b) [124I]-FIAC in athymic nude mice
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AsPC-1 IC50

MIA PaCa-2 - IC50

3.98 µM

25.87 µM

Source
1
2

gem treatment

percentage inhibition
at 20 µM

82%

60%

62%

58%

0.5 µM

1.0 µM

4

12.6 nM

42.6 nM

5

3

10 µM

Table A.5.2 Different sensitivities of AsPC-1 and MIA PaCa-2 to gemcitabine as reported in
literature.
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